

NOVANTA INC
Form 10-Q
November 06, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2018

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 001-35083

Novanta Inc.

(Exact name of registrant as specified in its charter)

New Brunswick, Canada (State or other jurisdiction of incorporation or organization)	98-0110412 (I.R.S. Employer Identification No.)
--	---

125 Middlesex Turnpike

Bedford, Massachusetts, USA (Address of principal executive offices)	01730 (Zip Code)
---	---------------------

(781) 266-5700

Edgar Filing: NOVANTA INC - Form 10-Q

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 2, 2018, there were 34,905,121 of the Registrant's common shares, no par value, issued and outstanding.

NOVANTA INC.

TABLE OF CONTENTS

Item No.	Page No.
<u>PART I — FINANCIAL INFORMATION</u>	1
ITEM 1. <u>FINANCIAL STATEMENTS</u>	1
<u>CONSOLIDATED BALANCE SHEETS (unaudited)</u>	1
<u>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</u>	2
<u>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)</u>	3
<u>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</u>	4
<u>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</u>	5
ITEM 2. <u>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	29
ITEM 3. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	41
ITEM 4. <u>CONTROLS AND PROCEDURES</u>	41
<u>PART II — OTHER INFORMATION</u>	43
ITEM 1. <u>LEGAL PROCEEDINGS</u>	43
ITEM 1A. <u>RISK FACTORS</u>	43
ITEM 2. <u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	43
ITEM 3. <u>DEFAULTS UPON SENIOR SECURITIES</u>	43
ITEM 4. <u>MINE SAFETY DISCLOSURES</u>	43
ITEM 5. <u>OTHER INFORMATION</u>	43
ITEM 6. <u>EXHIBITS</u>	44
<u>SIGNATURES</u>	46

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

	September 28, 2018	December 31, 2017
ASSETS		
Current assets		
Cash and cash equivalents	\$ 111,814	\$ 100,057
Accounts receivable, net of allowance of \$323 and \$554, respectively	88,921	81,482
Inventories	98,917	91,278
Prepaid income taxes and income taxes receivable	3,995	4,387
Prepaid expenses and other current assets	9,527	10,675
Total current assets	313,174	287,879
Property, plant and equipment, net	66,204	61,718
Deferred tax assets	8,059	7,052
Other assets	1,579	4,018
Intangible assets, net	150,648	155,048
Goodwill	219,772	210,988
Total assets	\$ 759,436	\$ 726,703
LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY		
Current liabilities		
Current portion of long-term debt	\$ 9,131	\$ 9,119
Accounts payable	48,306	39,793
Income taxes payable	2,400	5,942
Accrued expenses and other current liabilities	48,665	43,314
Total current liabilities	108,502	98,168
Long-term debt	247,293	225,500
Deferred tax liabilities	24,920	25,672
Income taxes payable	4,313	3,754
Other liabilities	14,732	15,141
Total liabilities	399,760	368,235
Commitments and contingencies (Note 14)		
Redeemable noncontrolling interest	—	46,923
Stockholders' equity:		
Common shares, no par value; Authorized shares: unlimited;	423,856	423,856

Edgar Filing: NOVANTA INC - Form 10-Q

Issued and outstanding: 34,916 and 34,595, respectively

Additional paid-in capital	45,940	33,309
Accumulated deficit	(90,736)	(127,740)
Accumulated other comprehensive loss	(19,384)	(17,880)
Total stockholders' equity	359,676	311,545
Total liabilities, noncontrolling interest and stockholders' equity	\$ 759,436	\$ 726,703

The accompanying notes are an integral part of these consolidated financial statements.

NOVANTA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Revenue	\$ 160,794	\$ 146,296	\$ 458,159	\$ 374,372
Cost of revenue	91,160	87,589	261,137	216,082
Gross profit	69,634	58,707	197,022	158,290
Operating expenses:				
Research and development and engineering	13,204	11,659	37,744	29,878
Selling, general and administrative	29,147	27,590	87,598	74,274
Amortization of purchased intangible assets	3,947	3,217	11,538	9,413
Restructuring, acquisition and divestiture related costs	2,341	3,834	4,805	6,232
Total operating expenses	48,639	46,300	141,685	119,797
Operating income	20,995	12,407	55,337	38,493
Interest income (expense), net	(2,396)	(2,111)	(7,315)	(4,874)
Foreign exchange transaction gains (losses), net	66	(661)	(164)	(176)
Other income (expense), net	(44)	(138)	(131)	(288)
Gain on acquisition of business	—	—	—	26,409
Income before income taxes	18,621	9,497	47,727	59,564
Income tax provision	3,632	1,131	8,276	6,934
Consolidated net income	14,989	8,366	39,451	52,630
Less: Net income attributable to noncontrolling interest	(435)	(834)	(1,986)	(1,444)
Net income attributable to Novanta Inc.	\$ 14,554	\$ 7,532	\$ 37,465	\$ 51,186

Earnings (loss) per common share attributable to Novanta Inc.

(Note 5):

Basic	\$ 0.61	\$ (0.00)	\$ 1.12	\$ 1.15
Diluted	\$ 0.60	\$ (0.00)	\$ 1.11	\$ 1.13
Weighted average common shares outstanding—basic	34,899	34,833	34,918	34,809
Weighted average common shares outstanding—diluted	35,485	34,833	35,469	35,235

The accompanying notes are an integral part of these consolidated financial statements.

NOVANTA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands of U.S. dollars)

(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 28,	September 29,	September 28,	September 29,
	2018	2017	2018	2017
Consolidated net income	\$ 14,989	\$ 8,366	\$ 39,451	\$ 52,630
Other comprehensive income (loss):				
Foreign currency translation adjustments, net of tax (1)	(490)	3,311	(2,482)	8,340
Pension liability adjustments, net of tax (2)	223	(45)	978	43
Total other comprehensive income	(267)	3,266	(1,504)	8,383
Total consolidated comprehensive income	14,722	11,632	37,947	61,013
Less: Comprehensive income attributable to noncontrolling interest	(435)	(834)	(1,986)	(1,444)
Comprehensive income attributable to Novanta Inc.	\$ 14,287	\$ 10,798	\$ 35,961	\$ 59,569

- (1) The tax effect on this component of comprehensive income was nominal for all periods presented.
- (2) The tax effect on this component of comprehensive income was nominal for all periods presented. See Note 4 for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

NOVANTA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

	Nine Months Ended	
	September 28, 2018	September 29, 2017
Cash flows from operating activities:		
Consolidated net income	\$39,451	\$ 52,630
Adjustments to reconcile consolidated net income to		
net cash provided by operating activities:		
Depreciation and amortization	27,386	22,440
Provision for inventory excess and obsolescence	1,765	1,837
Share-based compensation	5,475	4,223
Deferred income taxes	(3,309)	(2,913)
Earnings from equity-method investment	—	(104)
Gain on acquisition of business	—	(26,409)
Inventory acquisition fair value adjustment	—	4,754
Other	510	1,297
Changes in assets and liabilities which (used)/provided cash, excluding		
effects from business acquisitions:		
Accounts receivable	(5,747)	(3,859)
Inventories	(9,041)	(11,806)
Prepaid income taxes, income taxes receivable, prepaid expenses		
and other current assets	1,234	(5,806)
Accounts payable, income taxes payable, accrued expenses		
and other current liabilities	10,101	5,975
Other non-current assets and liabilities	(105)	(972)
Cash provided by operating activities	67,720	41,287
Cash flows from investing activities:		
Purchases of property, plant and equipment	(11,645)	(6,502)
Acquisition of businesses, net of cash acquired and working capital adjustments	(29,600)	(168,332)
Acquisition of assets	(1,225)	—
Other investing activities	213	44
Cash used in investing activities	(42,257)	(174,790)
Cash flows from financing activities:		
Borrowings under revolving credit facility	55,253	176,769
Repayments of long-term debt and revolving credit facility	(29,059)	(15,625)
Payments of debt issuance costs	—	(638)

Edgar Filing: NOVANTA INC - Form 10-Q

Payments of contingent considerations	—	(2,546)
Repurchase of common stock	(3,765)	(370)
Payments of withholding taxes from stock-based awards	(3,483)	(1,846)
Capital lease payments	(420)	(646)
Acquisition of noncontrolling interest	(30,800)	—
Cash provided by (used in) financing activities	(12,274)	155,098
Effect of exchange rates on cash and cash equivalents	(1,432)	2,446
Increase in cash and cash equivalents	11,757	24,041
Cash and cash equivalents, beginning of period	100,057	68,108
Cash and cash equivalents, end of period	\$ 111,814	\$ 92,149
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$6,716	\$ 3,512
Cash paid for income taxes	\$15,173	\$ 18,053
Income tax refunds received	\$2,245	\$ 185

The accompanying notes are an integral part of these consolidated financial statements.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 28, 2018

(Unaudited)

1. Basis of Presentation

Novanta Inc. and its subsidiaries (collectively referred to as “Novanta”, the “Company”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. Novanta combines deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to the customers’ demanding applications.

The accompanying unaudited interim consolidated financial statements have been prepared by the Company in United States (“U.S.”) dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted. The interim consolidated financial statements and notes included in this report should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

Prior to January 10, 2017, the Company had an approximately 41% ownership interest in Laser Quantum Limited (“Laser Quantum”), a privately held company located in the United Kingdom (“U.K.”), which was accounted for under the equity method of accounting. On January 10, 2017, the Company acquired an additional approximately 35% of the outstanding shares of Laser Quantum. As a result of this transaction, the Company’s ownership position in Laser Quantum increased to approximately 76%. Since January 10, 2017, Laser Quantum has been consolidated in the Company’s consolidated financial statements. On September 27, 2018, the Company acquired the remaining approximately 24% of the outstanding shares of Laser Quantum for an aggregate consideration of \$45.1 million in cash and restricted stock.

The Company’s unaudited interim financial statements are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of

contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which they are deemed to be necessary. The Company evaluates its estimates based on historical experience, current conditions and various other assumptions that it believes are reasonable under the circumstances. Actual results could differ significantly from those estimates.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Recent Accounting Pronouncements

The following table provides a brief description of recent Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”):

Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In March 2018, the FASB issued ASU 2018-05, “Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118.”	ASU 2018-05 allows SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the income tax effects of the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”). Companies have up to one year from the enactment of the Tax Reform Act (the “measurement period”) to obtain, prepare, and analyze the information that is needed in order to complete the accounting under Accounting Standards Codification (“ASC”) Topic 740. Any provisional amounts or adjustments to provisional amounts during the measurement period should be included in income from continuing operations as an adjustment to tax provision (benefit) in the reporting period in which the amounts are determined.	January 1, 2018.	The Company adopted ASU 2018-05 during the first quarter of 2018. See Note 12.
In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.”	ASU 2018-02 allows an entity to reclassify the income tax effects of the Tax Reform Act on items within accumulated other comprehensive income to retained earnings. ASU 2018-02 shall be applied either in the period of adoption or retrospectively to each period (or periods) in which the effects of the change in the U.S. federal corporate income tax rate in the Tax Reform Act is recognized.	January 1, 2019. Early adoption is permitted.	The Company is currently evaluating the impact of ASU 2018-02 on its consolidated financial statements.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718).”	ASU 2017-09 requires that an entity account for the effects of a modification unless (i) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (ii) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (iii) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 should be applied prospectively to an award modified on or after the adoption date.	January 1, 2018. Early adoption is permitted.	The Company adopted ASU 2017-09 during the first quarter of 2018. The adoption of ASU 2017-09 did not have a material impact on the Company’s consolidated financial statements.
In March 2017, the FASB issued ASU 2017-07, “Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.”	ASU 2017-07 requires employers that offer or maintain defined benefit plans to disaggregate the service component from the other components of net periodic benefit cost and provides guidance on the presentation of the service component and the other components of net periodic benefit cost in the statement of operations. ASU 2017-07 should be applied retrospectively for the presentation of net periodic benefit cost in the statement of operations.	January 1, 2018. Early adoption is permitted.	The Company retrospectively adopted ASU 2017-07 during the first quarter of 2018. The adoption of ASU 2017-07 resulted in the reclassification of \$0.1 million and \$0.4 million of the Company’s net periodic benefit cost related to its frozen U.K. pension plan from Selling, general and administrative expenses into Other income (expense) in the consolidated statement of operations for the three and nine months ended September 29, 2017, respectively.
In October 2016, the FASB issued ASU 2016-16, “Income Taxes	ASU 2016-16 requires that an entity recognize the income tax consequences of an intra-entity	January 1, 2018. Early adoption is	The Company adopted ASU 2016-16 during the first quarter of 2018 using the modified retrospective approach.

(Topic 740):
Intra-Entity Transfers
of Assets Other Than
Inventory.”

transfer of an asset other than
inventory in the period in which the
transfer occurs. ASU 2016-16 shall be
applied on a modified retrospective
basis through a cumulative-effect
adjustment directly to retained
earnings as of the beginning of the
period of adoption.

permitted.

The adoption resulted in the
reclassification of \$2.5 million of
prepaid income taxes and income
taxes receivable, of which \$2.2
million was recorded to Accumulated
deficit and \$0.3 million was
recognized as net deferred tax assets,
for the three months ended March 30,
2018. The Company will recognize
incremental deferred income tax
expense thereafter as these net
deferred tax assets are utilized.

7

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers – Deferral of the Effective Date.”	ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition,” and requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgements and changes in judgements and assets recognized from costs incurred to fulfill a contract. ASU 2015-14 deferred the effective date of ASU 2014-09 by one year.	January 1, 2018.	The Company adopted ASU 2014-09 during the first quarter of 2018 using the modified retrospective method. ASU 2014-09 has been applied to those contracts which were not completed as of January 1, 2018 and all new contracts entered into by the Company subsequent to January 1, 2018. All prior period financial statements and disclosures are presented in accordance with Topic 605. The adoption of ASU 2014-09 did not have an impact on the Company’s Accumulated deficit. See Note 2.
In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.”	ASU 2017-04 simplifies the accounting for goodwill impairment by removing Step-two of the goodwill impairment test, which requires a hypothetical purchase price allocation. ASU 2017-04 should be applied on a prospective basis.	January 1, 2020. Early adoption is permitted.	The Company adopted ASU 2017-04 during the second quarter of 2018. The adoption of ASU 2017-04 had no impact on the Company’s consolidated financial statements.
In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.”	ASU 2017-12 amends and simplifies existing guidance in order to better align a company’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. ASU 2017-12 should	January 1, 2019. Early adoption is permitted.	The Company does not expect the adoption of ASU 2017-12 to have a material impact on its consolidated financial statements.

be applied to hedging relationships existing on the date of adoption. The effect of the adoption should be reflected as of the beginning of the fiscal year of adoption.

<p>In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” In July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842) – Targeted Improvements.”</p>	<p>ASU 2016-02 requires a lessee to recognize on the balance sheet a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases and to disclose key information about leasing arrangements. ASU 2016-02 should be applied as of the beginning of the earliest period presented in the financial statements using a modified retrospective approach. ASU 2018-11 provides an additional (and optional) transition method which allows entities to apply ASU 2016-02 as of the adoption date and recognize a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption.</p>	<p>January 1, 2019. Early adoption is permitted.</p>	<p>As a result of the new standard, all of the Company’s operating leases longer than one year in duration will be recognized on the consolidated balance sheet as right-of-use assets with offsetting lease liabilities upon adoption of the standard. The Company has completed a qualitative assessment of its lease portfolio and is in the process of implementing a lease accounting software, collecting data and designing processes and controls to account for leases in accordance with the new standard. The Company plans to adopt the standard as of January 1, 2019 under the transition option provided in ASU 2018-11.</p>
--	---	--	---

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

2. Revenue

The Company recognizes revenue when control of promised goods or services is transferred to customers. The transfer of control generally occurs upon shipment, which is when title and risk of loss pass to the customer. The vast majority of the Company's revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for such products, which is generally at contractually stated prices. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.

Performance Obligations

Substantially all of the Company's revenue is recognized at a point in time, upon shipment, rather than over time.

At the request of its customers, the Company may perform professional services, generally for the maintenance and repair of products previously sold to those customers and for engineering services. Professional services are typically short in duration, mostly less than one month, and total less than 3% of the Company's consolidated revenue. Revenue is typically recognized at a point in time when control transfers to the customer upon completion of professional services. These services generally involve a single distinct performance obligation. The consideration expected to be received in exchange for such services is normally the contractually stated amount.

The Company occasionally sells separately priced non-standard/extended warranty services or preventative maintenance plans with the sale of products. The transfer of control over the service plans is over time. The Company recognizes the related revenue ratably over the terms of the service plans. The transaction price of a contract is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using the expected cost plus a margin.

The Company accounts for shipping and handling activities that occur after the transfer of control over the related goods as fulfillment activities rather than performance obligations. The shipping and handling fees charged to customers are recognized as revenue and the related costs are recorded in cost of revenue at the time of transfer of control.

Accounts Receivable

Credit is extended based upon an evaluation of the customer's financial condition. Accounts receivable are stated at their estimated net realizable value. The allowance for doubtful accounts is based on a variety of factors, including the

age of amounts outstanding relative to their contractual due dates, specific customer factors, and other known risks and economic trends. Standard payment terms are typically 30 days after shipment and may vary by the type and geographic location of the customer.

Warranties

The Company generally provides warranties for its products. The standard warranty period is typically 12 months to 24 months for the Photonics and Precision Motion segments and 12 months to 36 months for the Vision segment. The standard warranty period for product sales is accounted for under the provisions of ASC 450, "Contingencies," as the Company has the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. A provision for the estimated cost related to warranty is recorded to cost of revenue at the time revenue is recognized. The Company's estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that the Company's experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue.

Practical Expedients and Exemptions

The Company expenses incremental direct costs of obtaining a contract when incurred if the expected amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the consolidated statement of operations.

The Company does not adjust the promised amount of consideration for the effects of a financing component because the transfer of a promised good to a customer and the customer's payment for that good are typically one year or less.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The Company does not disclose the value of the remaining performance obligation for contracts with an original expected length of one year or less.

Contract Liabilities

Contract liabilities consist of deferred revenue and advance payments from customers, including amounts that are refundable. These contract liabilities are classified as either current or long-term liabilities in the consolidated balance sheet based on the timing of when the Company expects to recognize revenue. As of September 28, 2018 and January 1, 2018 (the date of adoption of Topic 606), contract liabilities were \$4.8 million and \$5.4 million, respectively, and are included in accrued expenses and other current liabilities and other liabilities in the accompanying consolidated balance sheets. The decrease in the contract liability balance during the nine months ended September 28, 2018 is primarily due to \$3.0 million of revenue recognized during the period that was included in the contract liability balance at the date of adoption, partially offset by cash payments received in advance of satisfying performance obligations.

Disaggregated Revenue

See Note 17 for the Company's disaggregation of revenue by segment, geography and end market.

3. Business Combinations

2018 Acquisitions

During the nine months ended September 28, 2018, the Company acquired two businesses with total cash considerations of \$33.5 million, including the acquisition of Zettlex Holdings Limited ("Zettlex"), for a total purchase price of \$32.0 million. The consolidated statements of operations include the operating results of the businesses from the dates of acquisition.

Zettlex

On May 1, 2018, the Company acquired 100% of the outstanding stock of Zettlex, a Cambridge, United Kingdom-based provider of inductive encoder products that provides absolute and accurate positioning, even in extreme operating environments, to OEMs in the medical and advanced industrial markets. The purchase price of £23.3 million (\$32.0 million), net of working capital adjustments, was financed with cash on hand and borrowings under the Company's revolving credit facility. The addition of Zettlex is expected to broaden the range of components and solutions that the Company can provide to customers by combining its commercial resources and application-specific competencies with Zettlex's technologies and strong team. Zettlex is included in the Company's

Precision Motion reportable segment.

The acquisition of Zettlex has been accounted for as a business combination. The allocation of the purchase price is based upon a valuation of assets acquired and liabilities assumed. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The fair values of intangible assets were based on valuations using an income approach, with estimates and assumptions provided by management of Zettlex and the Company. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The Company's estimates and assumptions in determining the estimated fair values of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information obtained with regards to facts and circumstances that existed as of the acquisition date. The purchase price allocation is preliminary as the Company is in the process of collecting additional information for the valuation of intangible assets and unrecognized tax benefits.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Based upon a preliminary valuation, the total purchase price was allocated as follows (in thousands):

	Purchase Price Allocation
Cash	\$ 3,776
Accounts receivable	2,237
Inventories	928
Property, plant and equipment	2,590
Intangible assets	14,585
Goodwill	11,649
Other assets	145
Total assets acquired	35,910
Accounts payable	509
Accrued expenses and other liabilities	894
Deferred tax liabilities	2,481
Total liabilities assumed	3,884
Total assets acquired, net of liabilities assumed	32,026
Less: cash acquired	3,776
Total purchase price, net of cash acquired	\$ 28,250

The fair value of intangible assets is comprised of the following (dollar amounts in thousands):

	Estimated Fair Value	Weighted Average Amortization Period
Developed technologies	\$ 3,027	10 years
Customer relationships	9,494	15 years
Trademarks and trade names	550	10 years
Backlog	1,514	1 year
Total	\$ 14,585	

The purchase price allocation resulted in \$14.6 million of identifiable intangible assets and \$11.6 million of goodwill. As the Zettlex acquisition is an acquisition of outstanding common shares, none of the resulting goodwill is deductible for tax purposes. Intangible assets are being amortized over their weighted average useful lives primarily based upon the pattern in which anticipated economic benefits from such assets are expected to be realized. The goodwill recorded

represents the anticipated incremental value of future cash flows potentially attributable to: (i) Zettlex's ability to grow its business with existing and new customers, including leveraging the Company's customer base; and (ii) cost improvements due to the integration of Zettlex operations into the Company's existing infrastructure.

The operating results of Zettlex were included in the Company's results of operations beginning on May 1, 2018. Zettlex contributed revenues of \$5.0 million and a loss before income taxes of \$1.4 million for the nine months ended September 28, 2018. Loss before income taxes for the nine months ended September 28, 2018 included amortization of purchased intangible assets of \$0.8 million and compensation expense of \$2.8 million recognized under earn-out agreements.

The pro forma financial information reflecting the operating results of Zettlex, as if it had been acquired as of January 1, 2017, would not differ materially from the operating results of the Company as reported for the year ended December 31, 2017.

Acquisition Costs

Acquisition-related costs are included in restructuring, acquisition and divestiture related costs in the consolidated statements of operations. Acquisition-related costs for current year acquisitions were \$0.5 million for the nine months ended September 28, 2018.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

2017 Acquisition

On July 3, 2017, the Company acquired 100% of the outstanding shares of W.O.M. World of Medicine GmbH (“WOM”), a Berlin, Germany-based provider of medical insufflators, pumps, and related disposables for OEMs in the minimally invasive surgical market, for a total purchase price of €118.1 million (\$134.9 million), net of working capital adjustments. WOM is included in the Company’s Vision reportable segment.

The unaudited pro forma information presented below includes the effects of business combination accounting resulting from the acquisition of WOM, including amortization of inventory fair value adjustments, amortization of intangible assets, interest expense on borrowings in connection with the acquisition, and the related tax effects, as though the acquisition had been consummated as of January 1, 2016. The unaudited pro forma financial information is presented for comparative purposes only and is not necessarily indicative of the results of operations that actually would have been achieved if the acquisition had taken place on January 1, 2016.

	Three Months Ended September 29, 2017	Nine Months Ended September 29, 2017
Revenue	\$ 146,296	\$ 415,134
Consolidated net income	\$ 12,547	\$ 56,754
Earnings per share attributable to Novanta Inc. – Basic	\$ 0.12	\$ 1.26
Earnings per share attributable to Novanta Inc. – Diluted	\$ 0.12	\$ 1.25

4. Accumulated Other Comprehensive Income (Loss)

Changes in accumulated other comprehensive income (loss) was as follows (in thousands):

Total Accumulated

Edgar Filing: NOVANTA INC - Form 10-Q

	Other Comprehensive Income (Loss)	Cumulative Translation Adjustments	Pension Liability Adjustments
Balance at December 31, 2017	\$ (17,880)	\$ (8,313)	\$ (9,567)
Other comprehensive income (loss)	(2,232)	(2,482)	250
Amounts reclassified from accumulated other comprehensive income (loss) ⁽¹⁾	728	—	728
Balance at September 28, 2018	\$ (19,384)	\$ (10,795)	\$ (8,589)

(1) The amounts reclassified from other comprehensive income (loss) were included in other income (expense), net in the consolidated statements of operations.

5. Earnings per Common Share

Earnings per common share is computed by dividing net income attributable to Novanta Inc., after redeemable noncontrolling interest redemption value adjustment, by the weighted average number of common shares outstanding during the period. The Company recognizes changes in the redeemable noncontrolling interest redemption value by adjusting the carrying amount of the redeemable noncontrolling interest as of the end of the period to the higher of: (i) the estimated redemption value assuming the end of the period is also the redemption date or (ii) the carrying value without any redemption value adjustments. Such adjustments are recorded in retained earnings in stockholders' equity instead of net income attributable to Novanta Inc. For both basic and diluted earnings per common share, such redemption value adjustments are included in the calculation of the numerator. For diluted earnings per common share, the denominator also includes the dilutive effect of outstanding restricted stock units, stock options, non-GAAP EPS performance-based restricted stock units and total shareholder return performance-based restricted stock units determined using the treasury stock method. Dilutive effects of contingently issuable shares are included in the weighted average dilutive share calculation when the contingencies have been resolved. For periods in which net losses are generated, the dilutive potential common shares are excluded from the calculation of diluted earnings per common share as the effect would be anti-dilutive.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The following table sets forth the computation of basic and diluted earnings per common share (amounts in thousands, except per share data):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Numerators:				
Consolidated net income	\$ 14,989	\$ 8,366	\$ 39,451	\$ 52,630
Less: Net income attributable to noncontrolling interest	(435)	(834)	(1,986)	(1,444)
Net income attributable to Novanta Inc.	14,554	7,532	37,465	51,186
Redeemable noncontrolling interest redemption value adjustment (see Note 15)	6,877	(7,585)	1,781	(11,303)
Net income (loss) attributable to Novanta Inc. after adjustment for redeemable noncontrolling interest redemption value	\$ 21,431	\$ (53)	\$ 39,246	\$ 39,883
Denominators:				
Weighted average common shares outstanding— basic	34,899	34,833	34,918	34,809
Dilutive potential common shares (1) (2)	586	—	551	426
Weighted average common shares outstanding— diluted	35,485	34,833	35,469	35,235
Antidilutive common shares excluded from above	—	—	—	—
Earnings (Loss) per Common Share Attributable to Novanta Inc.:				
Basic	\$ 0.61	\$ (0.00)	\$ 1.12	\$ 1.15
Diluted	\$ 0.60	\$ (0.00)	\$ 1.11	\$ 1.13

(1) 53,968 non-GAAP EPS performance restricted stock units granted to certain members of the executive management team and 213,219 shares of restricted stock issued to Laser Quantum non-controlling interest holders (see Note 15) are considered contingently issuable shares and are excluded from the calculation of the denominator as the contingent conditions had not been met as of the end of each period presented.

(2) Due to the Company's net loss position after adjustment of redeemable noncontrolling interest to estimated redemption value for the three months ended September 29, 2017, all potentially dilutive shares are excluded from the calculation of the denominator as their effect would have been anti-dilutive.

Common Share Repurchases

During the nine months ended September 28, 2018, the Company repurchased 57 thousand of its common shares in the open market for an aggregate purchase price of \$3.8 million at an average price of \$66.16 per share.

6. Fair Value Measurements

ASC 820, "Fair Value Measurements," establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the third is considered unobservable:

Level 1: Quoted prices for identical assets or liabilities in active markets which the Company can access

Level 2: Observable inputs other than those described in Level 1

Level 3: Unobservable inputs

Cash Equivalents

The Company's cash equivalents are highly liquid investments with original maturities of three months or less, which represent an asset the Company measures at fair value on a recurring basis. The Company determines the fair value of cash equivalents using a market approach based on quoted prices in active markets. The fair values of cash, accounts receivable, income taxes receivable,

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

accounts payable, income taxes payable and accrued expenses and other current liabilities approximate their carrying values because of their short-term nature.

Foreign Currency Contracts

The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain balance sheet foreign currency transaction exposures. The Company uses foreign currency forward contracts as a part of its strategy to manage exposures related to foreign currency denominated monetary assets and liabilities.

Contingent Consideration

On December 14, 2016, the Company acquired certain video signal processing and management technologies used in medical visualization solutions. Under the purchase and sale agreement, the owners are eligible to receive contingent consideration based on the achievement of certain revenue targets from 2018 to 2021. The undiscounted range of possible contingent consideration is zero to €5.5 million (\$6.6 million). If such targets are achieved, the contingent consideration would be payable in cash in four installments from 2019 to 2022. As the acquired assets did not meet the definition of a business, the fair value of the contingent consideration is recognized when probable and estimable and is capitalized as part of the cost of the acquired assets. In December 2017, the Company recorded an estimated fair value of \$1.3 million in contingent consideration, which is reported as a long-term liability in other liabilities on the consolidated balance sheet as of December 31, 2017. Based on the most recent projected revenues for fiscal years 2018 to 2021, the fair value of the contingent consideration was adjusted to \$2.4 million, which is reported as a long-term liability in other liabilities on the consolidated balance sheet as of September 28, 2018.

On February 19, 2015, the Company acquired Applimotion Inc. (“Applimotion”). Under the purchase and sale agreement for the Applimotion acquisition, the shareholders of Applimotion were eligible to receive contingent consideration based on the achievement of certain revenue targets for fiscal years 2015 to 2017. If such targets were achieved, the contingent consideration would be payable in cash in two installments in 2017 and 2018, respectively. The estimated fair value of the contingent consideration of \$1.0 million was determined based on the Monte Carlo valuation method and was recorded as part of the purchase price as of the acquisition date. As a result of Applimotion’s fiscal year 2015 and 2016 revenue results, contingent consideration of \$1.2 million was paid in the first quarter of 2017. Based on Applimotion’s fiscal year 2016 and 2017 revenue results, the fair value for the remaining contingent consideration was adjusted to \$2.8 million as of December 31, 2017. The Company paid \$2.8 million as the final Applimotion contingent consideration payment in January 2018.

The following table summarizes the fair values of the Company’s financial assets and liabilities as of September 28, 2018 (in thousands):

Quoted Prices in

Significant Other

Edgar Filing: NOVANTA INC - Form 10-Q

	Fair Value	Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
Assets				
Cash equivalents	\$ 2,109	\$ 2,109	\$ —	\$ —
Prepaid expenses and other current assets:				
Foreign currency forward contracts	132	—	132	—
	\$ 2,241	\$ 2,109	\$ 132	\$ —
Liabilities				
Accrued expenses and other current liabilities:				
Foreign currency forward contracts	\$ 33	\$ —	\$ 33	\$ —
Other liabilities:				
Contingent consideration - Long-term	2,438	—	—	2,438
	\$ 2,471	\$ —	\$ 33	\$ 2,438

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The following table summarizes the fair values of the Company's financial assets and liabilities as of December 31, 2017 (in thousands):

	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
Assets				
Cash equivalents	\$ 2,665	\$ 2,665	\$ —	\$ —
Prepaid expenses and other current assets:				
Foreign currency forward contracts	150	—	150	—
	\$ 2,815	\$ 2,665	\$ 150	\$ —
Liabilities				
Accrued expenses and other current liabilities:				
Contingent consideration - Current	\$ 2,800	\$ —	\$ —	\$ 2,800
Foreign currency forward contracts ⁽¹⁾	—	—	—	—
Other liabilities:				
Contingent consideration - Long-term	1,304	—	—	1,304
	\$ 4,104	\$ —	\$ —	\$ 4,104

(1) The unrealized loss from foreign currency forward contracts was nominal as of December 31, 2017.

Changes in the fair value of Level 3 contingent consideration during the nine months ended September 28, 2018 were as follows (in thousands):

	Contingent Consideration
Balance at December 31, 2017	\$ 4,104
Payments	(2,800)
Fair value adjustments	1,134
Balance at September 28, 2018	\$ 2,438

As of September 28, 2018, the significant unobservable inputs used in the fair value measurement of the Company's contingent consideration were projected revenues and a discount rate. Increases or decreases in the unobservable inputs would result in a higher or lower fair value measurement.

See Note 10 to Consolidated Financial Statements for a discussion of the estimated fair value of the Company's outstanding debt.

7. Foreign Currency Contracts

The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain foreign currency transaction exposures from future settlement of non-functional currency monetary assets and liabilities as of the end of a period. The Company does not enter into derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on the underlying hedged exposures. Furthermore, the Company manages its exposure to counterparty risks on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Beginning in September 2017, the Company commenced a foreign currency hedging program through the use of forward contracts as a part of its strategy to limit its exposures related to monetary assets and liabilities denominated in currencies other than the functional currency of the Company and its subsidiaries. These forward contracts are not designated as cash flow, fair value or net investment hedges. All changes in the fair value of these forward contracts are recognized in income before income taxes.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

As of September 28, 2018, the aggregate notional amount of the Company's foreign currency forward contracts was \$30.1 million and the related fair value was a net gain of \$0.1 million. As of December 31, 2017, the aggregate notional amount of the Company's foreign currency forward contracts was \$17.9 million and the related fair value was a net gain of \$0.2 million.

For the three and nine months ended September 28, 2018, the Company recognized an aggregate net loss of \$0.2 million and an aggregate net gain of \$0.7 million, respectively, which are included in foreign exchange transaction gains (losses) in the consolidated statement of operations. The Company did not have any open foreign currency contracts for the three and nine months ended September 29, 2017.

8. Goodwill and Intangible Assets

Goodwill

Goodwill is recorded when the consideration for a business combination exceeds the fair value of net tangible and identifiable intangible assets acquired. The Company tests its goodwill balances annually for impairment as of the beginning of the second quarter or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. The Company performed the most recent annual goodwill and indefinite-lived intangible asset impairment test as of the beginning of the second quarter of 2018 and noted no impairment of goodwill.

The following table summarizes changes in goodwill during the nine months ended September 28, 2018 (in thousands):

Balance at beginning of the period	\$210,988
Goodwill acquired from acquisitions	11,862
Effect of foreign exchange rate changes	(3,078)
Balance at end of the period	\$219,772

Goodwill by reportable segment as of September 28, 2018 was as follows (in thousands):

Reportable Segment		Precision	Total
Photonics	Vision		

Edgar Filing: NOVANTA INC - Form 10-Q

			Motion	
Goodwill	\$ 169,803	\$ 156,129	\$ 45,069	\$ 371,001
Accumulated impairment of goodwill	(102,461)	(31,722)	(17,046)	(151,229)
Total	\$ 67,342	\$ 124,407	\$ 28,023	\$ 219,772

Goodwill by reportable segment as of December 31, 2017 was as follows (in thousands):

	Reportable Segment			Precision	Total
	Photonics	Vision	Motion		
Goodwill	\$ 170,818	\$ 157,436	\$ 33,963		\$ 362,217
Accumulated impairment of goodwill	(102,461)	(31,722)	(17,046)		(151,229)
Total	\$ 68,357	\$ 125,714	\$ 16,917		\$ 210,988

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Intangible Assets

Intangible assets as of September 28, 2018 and December 31, 2017, respectively, are summarized as follows (in thousands):

	September 28, 2018			December 31, 2017		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Amortizable intangible assets:						
Patents and developed technologies	\$ 134,144	\$ (84,359)	\$ 49,785	\$ 130,890	\$ (77,295)	\$ 53,595
Customer relationships	140,539	(61,253)	79,286	131,809	(52,015)	79,794
Customer backlog	1,779	(761)	1,018	2,524	(2,284)	240
Non-compete covenant	2,514	(2,358)	156	2,514	(1,956)	558
Trademarks and trade names	16,064	(8,688)	7,376	15,708	(7,874)	7,834
Amortizable intangible assets	295,040	(157,419)	137,621	283,445	(141,424)	142,021
Non-amortizable intangible assets:						
Trade names	13,027	—	13,027	13,027	—	13,027
Totals	\$ 308,067	\$ (157,419)	\$ 150,648	\$ 296,472	\$ (141,424)	\$ 155,048

Amortizable intangible assets as of September 28, 2018 include intangible assets of \$1.1 million recognized in conjunction with the acquisition of certain customer relationships in September 2018.

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining useful lives. Amortization expense for patents and developed technologies is included in cost of revenue in the accompanying consolidated statements of operations. Amortization expense for customer relationships, definite-lived trademarks and trade names, and other intangible assets is included in operating expenses in the accompanying consolidated statements of operations. Amortization expense was as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Amortization expense – cost of revenue	\$ 2,492	\$ 2,741	\$ 7,461	\$ 6,078
Amortization expense – operating expenses	3,947	3,217	11,538	9,413

Total amortization expense	\$ 6,439	\$ 5,958	\$ 18,999	\$ 15,491
----------------------------	----------	----------	-----------	-----------

Estimated amortization expense for each of the five succeeding years and thereafter as of September 28, 2018 was as follows (in thousands):

Year Ending December 31,	Operating		
	Cost of Revenue	Expenses	Total
2018 (remainder of year)	\$ 2,532	\$ 4,068	\$ 6,600
2019	9,256	14,945	24,201
2020	8,338	12,602	20,940
2021	7,407	11,683	19,090
2022	6,289	9,829	16,118
Thereafter	15,963	34,709	50,672
Total	\$ 49,785	\$ 87,836	\$ 137,621

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

9. Supplementary Balance Sheet Information

The following tables provide the details of selected balance sheet items as of the periods indicated (in thousands):

Inventories

	September 28, 2018	December 31, 2017
Raw materials	\$ 61,509	\$ 57,277
Work-in-process	16,369	14,847
Finished goods	18,374	16,443
Demo and consigned inventory	2,665	2,711
Total inventories	\$ 98,917	\$ 91,278

Accrued Expenses and Other Current Liabilities

	September 28, 2018	December 31, 2017
Accrued compensation and benefits	\$ 23,926	\$ 17,348
Accrued warranty	5,041	4,835
Customer deposits	3,392	3,634
Other	16,306	17,497
Total	\$ 48,665	\$ 43,314

Accrued Warranty

	Nine Months Ended September 28, 2018	September 29, 2017
Balance at beginning of the period	\$4,835	\$ 3,142

Edgar Filing: NOVANTA INC - Form 10-Q

Provision charged to cost of revenue	2,503	2,084
Warranty liabilities acquired from acquisitions	—	1,307
Use of provision	(2,243)	(1,818)
Foreign currency exchange rate changes	(54)	58
Balance at end of period	\$5,041	\$ 4,773

10. Debt

Debt consisted of the following (in thousands):

	September 28, 2018	December 31, 2017
Senior Credit Facilities – term loan	\$ 9,200	\$9,200
Less: unamortized debt issuance costs	(69)	(81)
Total current portion of long-term debt	\$ 9,131	\$9,119
Senior Credit Facilities – term loan	\$ 69,925	\$79,125
Senior Credit Facilities – revolving credit facility	179,748	149,453
Less: unamortized debt issuance costs	(2,380)	(3,078)
Total long-term debt	\$ 247,293	\$ 225,500
Total Senior Credit Facilities	\$ 256,424	\$ 234,619

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Senior Credit Facilities

In August 2017, the Company entered into an amendment (the “Third Amendment”) to the second amended and restated credit agreement, dated as of May 19, 2016 (the “Second Amended and Restated Credit Agreement”). The Third Amendment increased the revolving credit facility under the Second Amended and Restated Credit Agreement by \$100 million, from \$225 million to \$325 million, and reset the uncommitted accordion feature to \$125 million for potential future expansion. Additionally, the Third Amendment increased the term loan balance from \$65.6 million to \$90.6 million. Under the Third Amendment, the Company is required to pay quarterly scheduled principal repayments of \$2.3 million beginning in October 2017, with the final installment of \$56.1 million due upon maturity in May 2021. Quarterly installments due in the next twelve months under the term loan amount to \$9.2 million and are classified as a current liability on the consolidated balance sheet. The Company borrowed \$55.3 million under the revolving credit facility in the nine months ended September 28, 2018 to fund the acquisition of Zettlex and the remaining 24% of outstanding shares of Laser Quantum. The Company repaid \$9.2 million of its term loan and \$19.9 million of borrowings under its revolving credit facility in the nine months ended September 28, 2018.

On February 26, 2018, the Company entered into a fourth amendment (the “Fourth Amendment”) to the Second Amended and Restated Credit Agreement. The Fourth Amendment increased the maximum consolidated leverage ratio from 3.00 to 3.50, increased the maximum consolidated leverage ratio for permitted acquisitions and stock repurchases from 2.50 to 3.00, increased the maximum consolidated leverage ratio for a designated acquisition from 3.00 to 3.50, and increased the maximum consolidated leverage ratio for four consecutive quarters following a designated acquisition from 3.50 to 4.00. The Fourth Amendment also made certain other technical changes to the Second Amended and Restated Credit Agreement.

The Company is required to satisfy certain financial and non-financial covenants under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement also contains customary events of default. The Company was in compliance with these covenants as of September 28, 2018.

Liens

The Company’s obligations under the Senior Credit Facilities are secured, on a senior basis, by a lien on substantially all of the assets of Novanta Inc. and its U.S., U.K. and German subsidiaries and guaranteed by Novanta Inc. and these subsidiaries.

Fair Value of Debt

As of September 28, 2018 and December 31, 2017, the outstanding balance of the Company’s debt approximated its fair value based on current rates available to the Company for debt of similar maturities. The fair value of the Company’s debt is classified as Level 2 under the fair value hierarchy.

11. Share-Based Compensation

The table below summarizes share-based compensation expense recorded in the consolidated statements of operations (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Selling, general and administrative	\$ 1,523	\$ 1,336	\$ 5,021	\$ 3,911
Research and development and engineering	114	59	306	156
Cost of revenue	58	41	148	156
Total share-based compensation expense	\$ 1,695	\$ 1,436	\$ 5,475	\$ 4,223

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Share-based compensation reported in selling, general and administrative expenses during each of the nine-month periods ended September 28, 2018 and September 29, 2017, respectively, included \$0.5 million of expense related to deferred stock units granted to the members of the Company’s Board of Directors.

Restricted Stock Units and Deferred Stock Units

The Company’s restricted stock units (“RSUs”) have generally been issued with vesting periods ranging from three years to five years and vest based solely on service conditions. Accordingly, the Company recognizes compensation expense on a straight-line basis over the requisite service period. The Company reduces the compensation expense by an estimated forfeiture rate which is based on anticipated forfeitures and historical forfeiture experience.

Deferred stock units (“DSUs”) are granted to the members of the Company’s Board of Directors. The compensation expense associated with the DSUs is recognized in full on the date of grant, as DSUs are fully vested and non-forfeitable upon grant.

The table below summarizes activities relating to RSUs and DSUs issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the nine months ended September 28, 2018:

	Shares	Weighted Average Grant Date Fair Value
	(In thousands)	
Unvested at December 31, 2017	614	\$ 18.35
Granted	123	\$ 54.36
Vested	(186)	\$ 18.52
Forfeited	(27)	\$ 24.53
Unvested at September 28, 2018	524	\$ 26.39
Expected to vest as of September 28, 2018	500	

The total fair value of RSUs and DSUs that vested during the nine months ended September 28, 2018 was \$10.2 million based on the market price of the underlying stock on the date of vesting.

Performance Stock Units

The Company granted two types of performance-based stock awards to certain members of the executive management team: non-GAAP EPS performance-based restricted stock units (“EPS-PSUs”) and relative total shareholder return performance-based restricted stock units (“TSR-PSUs”). Both types of performance-based restricted stock units generally cliff vest on the first day following the end of the three-year performance period.

The number of common shares to be issued upon settlement following vesting of the EPS-PSUs is determined based on the Company’s cumulative non-GAAP EPS over the three-year performance period against the target established by the Company’s Compensation Committee at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

The number of shares to be issued upon settlement following vesting of the TSR-PSUs is determined based on the relative market performance of the Company’s common stock compared to the Russell 2000 Index over the three-year performance period using a payout formula established by the Company’s Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense based on the fair value of the TSR-PSUs, determined using the Monte-Carlo valuation model as of the grant date, on a straight-line basis from the grant date to the end of the three-year performance period. Compensation expense will not be affected by the number of TSR-PSUs that will actually vest at the end of the three-year performance period.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The table below summarizes the activities relating to the performance-based awards issued and outstanding under the Company's Amended and Restated 2010 Incentive Plan during the nine months ended September 28, 2018:

	Shares	Weighted
	(In thousands)	Average Grant
		Date Fair Value
Unvested at December 31, 2017	89	\$ 24.00
Granted	48	\$ 62.17
Vested	—	\$ —
Forfeited	—	\$ —
Unvested at September 28, 2018	137	\$ 37.28

The fair value of the TSR-PSUs at the date of grant was estimated using the Monte-Carlo valuation model with the following assumptions:

	Nine	
	Months	
	Ended	
	September	
	28, 2018	
Grant-date stock price	\$ 53.85	
Expected volatility	30.35	%
Risk-free interest rate	2.37	%
Expected annual dividend yield	—	
Fair value	\$ 70.49	

12. Income Taxes

The Company determines its estimated annual effective tax rate at the end of each interim period based on full-year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period with the cumulative effect of any changes in the

estimated annual effective tax rate being recorded in the fiscal quarter in which the change is determined. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada's statutory tax rate of 29.0% in the determination of the estimated annual effective tax rate.

The Company's effective tax rate of 19.5% for the three months ended September 28, 2018 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, including the benefit of the new 21% U.S. corporate income tax rate, estimated deductions for Foreign Derived Intangible Income under the Tax Reform Act, and U.K. patent box deductions and other tax credits; offset by non-deductible expenses recognized under an earn-out agreement in connection with the Zettlex acquisition.

The Company's effective tax rate of 17.3% for the nine months ended September 28, 2018 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, including the benefit of the new 21% U.S. corporate income tax rate, estimated deductions for Foreign Derived Intangible Income under the Tax Reform Act, U.K. patent box deductions and other tax credits, and windfall tax benefits upon vesting of certain equity awards during the period; offset by non-deductible expenses recognized under an earn-out agreement in connection with the Zettlex acquisition.

The Company's effective tax rate of 11.9% for the three months ended September 29, 2017 differs from the Canadian statutory rate of 29.0% due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, recognition of net tax benefits associated with uncertain tax positions upon expiration of statute of limitations and conclusion of income tax audits, and other discrete items for the period.

The Company's effective tax rate of 11.6% for the nine months ended September 29, 2017 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, the impact associated with establishing control over Laser Quantum upon the acquisition of an additional approximately 35% of Laser Quantum's outstanding shares, recognition of net tax benefits associated with uncertain tax positions upon expiration of statute of limitations and conclusion of income tax audits, and other discrete items for the period. The Company reported a nontaxable gain of \$26.4 million on its previously-held Laser Quantum equity interest and wrote off \$1.5 million of Laser

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

Quantum related deferred tax liability, which had a combined 13.7% favorable impact on the effective tax rate for the nine months ended September 29, 2017.

The Company maintains a valuation allowance on some of its deferred tax assets in certain jurisdictions. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized.

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act significantly changes U.S. tax law by, among other things, lowering the U.S. corporate income tax rate from 35% to 21% effective January 1, 2018, implementing a territorial tax system, providing a one-time transition toll charge (“Toll Charge”) on accumulated foreign earnings, creating a new limitation on deductible interest expense and modifying the limitation on officer compensation.

As a result of the Tax Reform Act, the Company was required to revalue certain deferred tax assets and liabilities at the newly enacted 21% U.S. federal corporate income tax rate. This revaluation resulted in an additional income tax provision of \$2.8 million for the year ended December 31, 2017 and a corresponding reduction in the net deferred tax assets and liabilities. Because of the ownership structure of the Company, the Company’s foreign entities outside the U.S. are not considered controlled foreign corporations of the U.S. company, as defined under U.S. tax principles, and accordingly, the accumulated earnings of these foreign subsidiaries are not subject to the one-time Toll Charge under the Tax Reform Act.

ASC 740, “Income Taxes,” requires a company to record the effects of a tax law change in the period of enactment. ASU 2018-05 allows a company to record a provisional amount when it does not have the necessary information available, prepared, or analyzed in reasonable detail to complete its accounting for the changes in the Tax Reform Act. The measurement period ends when the company has obtained, prepared and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from the date of enactment of the Tax Reform Act. The Company currently anticipates finalizing and recording any resulting adjustments by December 2018.

During the nine months ended September 28, 2018, there were no changes made to the provisional amounts recognized in 2017 in connection with the enactment of the Tax Reform Act. The Company will continue to analyze the effects of the Tax Reform Act. Additional impacts from the Tax Reform Act will be recorded as they are identified during the measurement period as provided for in ASU 2018-05. The final impact of the Tax Reform Act may differ from the provisional amounts that have been recognized, possibly materially, due to, among other things, changes in the Company’s interpretation of the Tax Reform Act, legislative or administrative actions to clarify the intent of the statutory language that differ from the Company’s current interpretation, any changes in accounting standards for income taxes or related interpretations in response to the Tax Reform Act, or any updates or changes to estimates utilized to calculate the impacts, including changes to current year earnings estimates and applicable foreign exchange rates. Additionally, the Company’s U.S. tax returns for 2017 will be filed during the fourth quarter of 2018, and any changes to the tax positions for temporary differences compared to the estimates used for the provisional amounts will be recorded in the period in which they are identified. During the three and nine months ended September 28, 2018,

the Company recorded estimates for certain deductions now available in 2018 under the Tax Reform Act. These estimates may be subject to revision as future guidance or clarification is received from the U.S. taxing authorities.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

13. Restructuring, Acquisition and Divestiture Related Costs

The following table summarizes restructuring, acquisition and divestiture related costs in the accompanying consolidated statements of operations (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
2018 restructuring	\$ 137	\$ —	\$ 1,125	\$ —
2016 restructuring	—	—	—	186
2011 restructuring	—	—	—	14
Total restructuring and divestiture related charges	137	—	1,125	200
Acquisition and related charges	2,204	3,834	3,680	6,032
Total restructuring, acquisition and divestiture related costs	\$ 2,341	\$ 3,834	\$ 4,805	\$ 6,232

2018 Restructuring

During the second quarter of 2018, the Company initiated a program to integrate manufacturing operations as a result of recent acquisition activities. During the three and nine months ended September 28, 2018, the Company recorded \$0.1 million and \$1.1 million, respectively, in severance and related costs in connection with the 2018 restructuring plan. These costs were reported in the Vision reportable segment. The Company anticipates completing the 2018 restructuring program during the third quarter of 2019 and expects to incur additional restructuring charges of \$1.2 million to \$1.5 million related to the 2018 restructuring program in the Vision reportable segment in the next twelve months.

2016 Restructuring

During the third quarter of 2015, the Company initiated the 2016 restructuring program, which included consolidating certain manufacturing operations to optimize its facility footprint and better utilize resources, and reducing redundant costs due to productivity cost savings and business volume reductions. As of September 28, 2018, the Company incurred cumulative costs related to this restructuring plan totaling \$6.5 million. The plan was completed in 2017.

Rollforward of Accrued Expenses Related to Restructuring

The following table summarizes the accrual activities, by component, related to the Company's restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):

Total	Severance	Facility	Other
-------	-----------	----------	-------

Edgar Filing: NOVANTA INC - Form 10-Q

Balance at December 31, 2017	\$806	\$ 39	\$ 763	\$ 4
Restructuring charges	1,125	1,082	—	43
Cash payments	(512)	(187)	(282)	(43)
Non-cash write-offs and other adjustments	(11)	(11)	—	—
Balance at September 28, 2018	\$1,408	\$ 923	\$ 481	\$ 4

Acquisition and Related Charges

Acquisition related costs in connection with business combinations, including finders' fees, legal, valuation, and other professional or consulting fees, totaled \$0.5 million and \$0.9 million for the three and nine months ended September 28, 2018, respectively, and \$3.8 million and \$6.0 million for the three and nine months ended September 29, 2017, respectively. Acquisition related costs recognized under earn-out agreements in connection with acquisitions totaled \$1.7 million and \$2.8 million for the three and nine months ended September 28, 2018, respectively. The majority of acquisition related costs for the three and nine months ended September 28, 2018 were included in the Company's Precision Motion reportable segment.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

14. Commitments and Contingencies

Leases

The Company leases certain equipment and facilities under operating and capital lease agreements. There have been no material changes to the Company's leases through September 28, 2018 from those discussed in Note 16 to Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, other than a twelve-year extension (the "First Amendment to Amended and Restated Lease") to the Company's lease for its Bedford, Massachusetts headquarters signed in May 2018. Under the terms of the First Amendment to Amended and Restated Lease, the expiration date of the Bedford, Massachusetts lease is extended from May 31, 2019 to May 31, 2031. The Company's annual rental payment under the First Amendment to Amended and Restated Lease is \$1.8 million with 2.5% annual escalations. Total future minimum lease payments under the First Amendment to Amended and Restated Lease is \$26.4 million as of September 28, 2018.

Purchase Commitments

There have been no material changes to the Company's purchase commitments since December 31, 2017.

Legal Contingencies

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company reviews the status of each significant matter and assesses the potential financial exposure on a quarterly basis. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available as of the date of the consolidated balance sheet. As additional information becomes available, the Company reassesses the potential liability related to any pending claims and litigation and may revise its estimates. The Company does not believe that the outcome of these claims will have a material adverse effect on its consolidated financial statements but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect on its consolidated financial statements.

Guarantees and Indemnifications

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which he or she is involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of the Company's officers and directors are also

a party to indemnification agreements with the Company. These indemnification agreements provide, among other things, that the director and officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such officer or director in connection with any proceeding by reason of his or her relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and exclusions from indemnification, and the minimum levels of directors' and officers' liability insurance to be maintained by the Company.

15. Redeemable Noncontrolling Interest

As a result of the Company's acquisition of additional outstanding shares of Laser Quantum from the remaining shareholders on January 10, 2017, the Company increased its ownership position in Laser Quantum from approximately 41% to approximately 76% and began to consolidate Laser Quantum in the consolidated financial statements. As part of the purchase agreement, the Company and the remaining shareholders entered into a call and put option agreement for the purchase and sale, in 2020, of all remaining Laser Quantum shares held by the remaining shareholders, subject to certain conditions. As a result of the put option held by the remaining shareholders, the noncontrolling interest was considered a redeemable equity instrument and was presented as temporary equity on the

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

consolidated balance sheet. The proportionate share of the net income from Laser Quantum attributable to the noncontrolling interest was reported as a reduction to the consolidated net income in the Company's consolidated statement of operations and an increase to the carrying value of the redeemable noncontrolling interest.

The initial value of the noncontrolling interest was measured at a fair value of £17.7 million (\$21.6 million) as of January 10, 2017. This was determined using a combination of the discounted cash flow method (an income approach), the guideline public company method (a market approach), and the subject company transaction method (a market approach). On the consolidated balance sheet, the Company reported the redeemable noncontrolling interest at the higher of (i) the carrying value without any redemption value adjustments or (ii) the estimated redemption value as of the end of the reporting period. The estimated redemption value was determined as of the end of the reporting period as if it were also the redemption date for the instrument. The resulting adjustments were recorded in retained earnings in shareholders' equity and did not affect net income attributable to Novanta Inc. However, these adjustments were included in the determination of earnings per common share (See Note 5).

On September 27, 2018, the Company acquired the remaining approximately 24% of the outstanding shares of Laser Quantum for an aggregate consideration of \$45.1 million, consisting of \$30.7 million of cash and 213,219 shares of the Company's restricted stock. The restricted stock will become fully vested upon achievement of certain milestones included in the restricted stock agreement. Restricted stock not otherwise vested as of December 31, 2025 will be subject to forfeiture. The acquisition was accounted for as a transaction among shareholders. No gain or loss was recognized in the consolidated statements of operations for the three and nine months ended September 28, 2018. The difference between the carrying amount on the balance sheet prior to the acquisition of the redeemable noncontrolling interest and the purchase price was recorded as an adjustment to retained earnings in stockholders' equity. The following table summarizes the changes in the Company's redeemable noncontrolling interest in the nine months ended September 28, 2018 (in thousands):

	Redeemable Noncontrolling Interest
Balance as of December 31, 2017	\$ 46,923
Net income attributable to noncontrolling interest	1,986
Redeemable noncontrolling interest redemption value adjustment	(1,781)
Foreign currency translation	(1,926)
Acquisition of noncontrolling interest	(45,202)
Balance as of September 28, 2018	\$ —

16. Related Party Transactions

Certain members of the Company's board of directors currently serve on the board of directors or as an advisor of companies that are customers of the Company. All contracts with related parties are executed at arm's length in the ordinary course of business. The aggregate revenue from these customers was \$9.4 million and \$29.7 million for the three and nine months ended September 28, 2018, respectively. There was \$3.9 million in accounts receivable due from these customers as of September 28, 2018. There were no material transactions with related parties in the three and nine months ended September 29, 2017.

17. Segment Information

Reportable Segments

The Company evaluates the performance of, and allocates resources to, its segments based on revenue, gross profit and operating profit. The Company's reportable segments have been identified based on commonality and adjacency of technologies, applications and customers amongst the Company's individual product lines. The Company determined that disclosing revenue by specific product was impracticable due to the highly customized and extensive portfolio of products offered to customers.

25

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The Company operates in three reportable segments: Photonics, Vision, and Precision Motion. The reportable segments and their principal activities are described below.

Photonics

The Photonics segment designs, manufactures and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products to customers worldwide. The segment serves highly demanding photonics-based applications such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Vision

The Vision segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators, pumps and related disposables; surgical displays and operating room integration technologies; optical data collection and machine vision technologies; radio frequency identification ("RFID") technologies; thermal printers; spectrometry technologies; and embedded touch screen solutions. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Precision Motion

The Precision Motion segment designs, manufactures and markets optical and inductive encoders, precision motor and motion control technology, air bearing spindles and precision machined components to customers worldwide. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Reportable Segment Financial Information

Revenue, gross profit, gross profit margin, operating income (loss), and depreciation and amortization expenses by reportable segment were as follows (in thousands, except percentage data):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Revenue				
Photonics	\$61,285	\$ 61,882	\$187,178	\$ 170,503
Vision	62,113	58,150	172,145	124,943

Edgar Filing: NOVANTA INC - Form 10-Q

Precision Motion	37,396	26,264	98,836	78,926
Total	\$ 160,794	\$ 146,296	\$ 458,159	\$ 374,372

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Gross Profit				
Photonics	\$ 29,218	\$ 28,966	\$ 89,510	\$ 77,423
Vision	24,160	19,792	64,322	47,378
Precision Motion	16,788	10,291	44,750	34,558
Unallocated Corporate and Shared Services	(532)	(342)	(1,560)	(1,069)
Total	\$ 69,634	\$ 58,707	\$ 197,022	\$ 158,290

26

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

	Three Months Ended				Nine Months Ended			
	September 28,		September 29,		September 28,		September 29,	
	2018		2017		2018		2017	
Gross Profit Margin								
Photonics	47.7	%	46.8	%	47.8	%	45.4	%
Vision	38.9	%	34.0	%	37.4	%	37.9	%
Precision Motion	44.9	%	39.2	%	45.3	%	43.8	%
Total	43.3	%	40.1	%	43.0	%	42.3	%

	Three Months Ended				Nine Months Ended			
	September 28,		September 29,		September 28,		September 29,	
	2018		2017		2018		2017	
Operating Income (Loss)								
Photonics			\$ 14,595	\$ 15,367	\$ 46,102	\$ 36,138		
Vision			5,380	846	6,246	4,893		
Precision Motion			8,818	5,493	25,037	20,238		
Unallocated Corporate and Shared Services			(7,798)	(9,299)	(22,048)	(22,776)		
Total			\$ 20,995	\$ 12,407	\$ 55,337	\$ 38,493		

	Three Months Ended				Nine Months Ended			
	September 28,		September 29,		September 28,		September 29,	
	2018		2017		2018		2017	
Depreciation and Amortization Expenses								
Photonics			\$ 2,997	\$ 3,666	\$ 9,030	\$ 10,693		
Vision			5,100	4,362	15,371	9,276		
Precision Motion			1,020	588	2,364	1,746		
Unallocated Corporate and Shared Services			82	248	621	725		
Total			\$ 9,199	\$ 8,864	\$ 27,386	\$ 22,440		

Revenue by Geography

The Company aggregates geographic revenue based on the customer location where products are shipped. Revenue from these customers was as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28,	September 29,	September 28,	September 29,
	2018	2017	2018	2017

Edgar Filing: NOVANTA INC - Form 10-Q

	2018	2017	2018	2017
United States	\$63,073	\$ 58,949	\$181,653	\$ 157,778
Germany	23,089	17,728	64,170	46,807
Rest of Europe	30,222	27,152	80,629	55,164
China	17,516	15,459	51,486	40,920
Rest of Asia-Pacific	24,882	23,769	74,589	64,511
Other	2,012	3,239	5,632	9,192
Total	\$160,794	\$ 146,296	\$458,159	\$ 374,372

27

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

AS OF SEPTEMBER 28, 2018

(Unaudited)

The majority of revenue from our Photonics, Vision and Precision Motion segments is generated from sales to customers within the United States and Europe. Each segment also generates revenue across the other geographies, with no significant concentration of any segment's remaining revenue.

Revenue by End Market

The Company primarily operates in two end markets: the advanced industrial market and the medical market. Revenue by end market was approximately as follows:

	Three Months Ended				Nine Months Ended			
	September 28, 2018		September 29, 2017		September 28, 2018		September 29, 2017	
Advanced Industrial	50	%	50	%	50	%	55	%
Medical	50	%	50	%	50	%	45	%
Total	100	%	100	%	100	%	100	%

The majority of revenue from the Photonics and Precision Motion segments is generated from sales to customers in the advanced industrial market. The majority of revenue from the Vision segment is generated from sales to customers in the medical market.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, our belief that the Purchasing Managers Index (PMI) may provide an indication of the impact of general economic conditions on our sales into the advanced industrial end market; our strategy; anticipated financial performance; expected liquidity and capitalization; expectations regarding acquisitions; drivers of revenue growth; management's plans and objectives for future operations, expenditures and product development and investments in research and development; business prospects; potential of future product releases; anticipated revenue performance; changes in accounting principles and changes in actual or assumed tax liabilities; anticipated impact from the U.S. Tax Cuts and Jobs Act; and expectations regarding tax exposures. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: the PMI not providing a good indication of the impact of general economic conditions on our sales into the advanced industrial end market in any particular period or at all; economic and political conditions and the effects of these conditions on our customers' businesses and level of business activities; negative effect on global economic conditions, financial markets and our business as a result of the United Kingdom's plan for withdrawal from the European Union and the actions of the current U.S. government, including its policies on trade tariffs and reactions from other countries to any new tariffs imposed by the U.S.; our significant dependence upon our customers' capital expenditures, which are subject to cyclical market fluctuations; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our information technology systems; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; our failure to comply with local import and export regulations in the jurisdictions in which we operate; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business or grow acquired businesses; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors' products; disruptions in the supply of certain key components and other goods from our suppliers; production difficulties and product delivery delays or disruptions; our compliance, or our failure to comply, with various federal, state and foreign regulations; our exposure to medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; changes in governmental regulation of our business or products; our compliance, or failure to comply, with environmental regulations; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; changes in tax laws, and fluctuations in our effective tax rates; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; volatility in the market price for our common shares; our ability to access cash and other assets of our subsidiaries; provisions of our articles of incorporation delaying or preventing a change in control; our significant existing indebtedness limiting our ability to engage in certain activities; and our failure to maintain

appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company's operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 under the heading "Risk Factors." In this Quarterly Report on Form 10-Q, the words "anticipates," "believes," "expects," "intends," "future," "could," "estimates," "plans," "would," "should," "potential," "continues," and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such statement to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.

Accounting Period

The interim financial statements of Novanta Inc. and its subsidiaries (collectively referred to as the "Company", "we", "us", "our") are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

Business Overview

We are a global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.

Reportable Segments

We operate in three reportable segments: Photonics, Vision, and Precision Motion. The reportable segments and their principal activities consist of the following:

Photonics

Our Photonics segment designs, manufactures and markets photonics-based solutions, including laser scanning and laser beam delivery, CO₂ laser, continuous wave and ultrafast laser, and optical light engine products to customers worldwide. The segment serves highly demanding photonics-based applications such as industrial material processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Vision

Our Vision segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators, pumps and related disposables; surgical displays and operating room integration technologies; optical data collection and machine vision technologies; radio frequency identification (“RFID”) technologies; thermal printers; spectrometry technologies; and embedded touch screen solutions. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Precision Motion

Our Precision Motion segment designs, manufactures and markets optical and inductive encoders, precision motor and motion control technology, air bearing spindles and precision machined components to customers worldwide. The vast majority of the segment's product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

End Markets

We primarily operate in two end markets: the advanced industrial market and the medical market.

Advanced Industrial Market

For the three and nine months ended September 28, 2018, the advanced industrial market accounted for approximately 50% of our revenue. Revenue from our products sold to the advanced industrial market is affected by a number of factors, including changing technology requirements and preferences of our customers, productivity or quality investments in a manufacturing environment, the financial condition of our customers, changes in regulatory requirements and laws, and general economic conditions. We believe that the Purchasing Managers Index (PMI) on

manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on our sales into the advanced industrial market.

Medical Market

For the three and nine months ended September 28, 2018, the medical market accounted for approximately 50% of our revenue. Our revenue from products sold to the medical market is generally affected by hospital and other health care provider capital spending, changes in regulatory requirements and laws, aggregation of purchasing by healthcare networks, trends in surgical procedures, changes in technology requirements, changes in customers or patient preferences, and general demographic trends.

Strategy

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including:

- disciplined focus on our diversified business model of providing functionality to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets;
- improving our business mix to increase medical sales as a percentage of total revenue by:
 - introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment;
 - deepening our key account management relationships with and driving cross selling of our product offerings to leading medical equipment manufacturers; and
 - pursuing complementary medical technology acquisitions;
- increasing our penetration of high growth advanced industrial applications, such as laser materials processing, robotics, automation and metrology, by working closely with OEM customers to launch application specific products that closely match the requirements of each application;
- broadening our portfolio of enabling proprietary technologies and capabilities through increased investment in new product development, expanded sales and marketing channels to reach target customers, and investments in application development to further penetrate existing customers, while expanding the applicability of our solutions to new markets;
- broadening our product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications, including increasing our recurring revenue streams such as services, spare parts and consumables;
- improving our existing operations to expand profit margins and improve customer satisfaction by implementing lean manufacturing principles and strategic sourcing across our major production sites; and
- attracting, retaining, and developing world-class talented and motivated employees.

Significant Events and Updates

Acquisition of Zettlex Holdings Limited

On May 1, 2018, we acquired 100% of the outstanding stock of Zettlex Holdings Limited (“Zettlex”), a Cambridge, United Kingdom-based provider of inductive encoder products that provides absolute and accurate positioning, even in extreme operating environments, to OEMs in the medical and advanced industrial markets. The purchase price of £23.3 million (\$32.0 million), net of working capital adjustments, was financed with cash on hand and borrowings under our revolving credit facility. We expect that the addition of Zettlex will broaden the range of components and solutions that we can provide our customers by combining our commercial resources and application-specific competencies with Zettlex's technologies and strong team. Zettlex is included in our Precision Motion reportable segment.

Acquisition of Noncontrolling Interest

On September 27, 2018, we acquired the remaining approximately 24% of the outstanding shares of Laser Quantum for an aggregate consideration of \$45.1 million in cash and restricted stock. The acquisition of these noncontrolling interests was accounted for as a transaction among shareholders. No gain or loss was recognized in the consolidated statement of operations. The total purchase price was financed with cash on hand and borrowings under our credit facility, and the issuance of 213,219 shares of restricted stock with a fair market value of \$14.4 million. The restricted stock will become fully vested upon achievement of certain milestones as specified in the restricted stock agreement. Restricted stock not otherwise vested as of December 31, 2025 will be subject to forfeiture.

Results of Operations for the Three and Nine Months Ended September 28, 2018 Compared with the Three and Nine Months Ended September 29, 2017

The following table sets forth our unaudited results of operations as a percentage of revenue for the periods indicated:

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Revenue	100.0 %	100.0 %	100.0 %	100.0 %
Cost of revenue	56.7	59.9	57.0	57.7
Gross profit	43.3	40.1	43.0	42.3
Operating expenses:				
Research and development and engineering	8.2	8.0	8.2	8.0
Selling, general and administrative	18.1	18.9	19.1	19.8
Amortization of purchased intangible assets	2.5	2.2	2.5	2.5
Restructuring, acquisition and divestiture related costs	1.5	2.6	1.0	1.7
Total operating expenses	30.2	31.6	30.9	32.0
Operating income	13.1	8.5	12.1	10.3
Interest income (expense), net	(1.5)	(1.4)	(1.6)	(1.3)
Foreign exchange transaction gains (losses), net	0.0	(0.5)	(0.0)	(0.0)
Other income (expense), net	(0.0)	(0.1)	(0.0)	(0.1)
Gain on acquisition of business	—	—	—	7.1
Income before income taxes	11.6	6.5	10.4	15.9
Income tax provision	2.3	0.8	1.8	1.9
Consolidated net income	9.3	5.7	8.6	14.1
Less: Net income attributable to noncontrolling interest	(0.3)	(0.6)	(0.4)	(0.4)
Net income attributable to Novanta Inc.	9.1 %	5.1 %	8.2 %	13.7 %

Overview of Financial Results

Total revenue for the three months ended September 28, 2018 increased \$14.5 million, or 9.9%, versus the prior year period. The effect of our current and prior year acquisitions resulted in an increase in revenue of \$3.2 million, or 2.2%. In addition, foreign currency exchange rates adversely impacted our revenue by \$0.5 million, or 0.3%, for the three months ended September 28, 2018.

Total revenue for the nine months ended September 28, 2018 increased \$83.8 million, or 22.4%, versus the prior year period. The effect of our current and prior year acquisitions resulted in an increase in revenue of \$49.7 million, or 13.3%. In addition, foreign currency exchange rates favorably impacted our revenue by \$5.3 million, or 1.4%, for the nine months ended September 28, 2018.

Operating income increased \$8.6 million from \$12.4 million for the three months ended September 29, 2017 to \$21.0 million for the three months ended September 28, 2018. This increase was primarily attributable to an increase in gross profit of \$10.9 million as a result of higher revenue, partially offset by an increase in operating expenses of \$2.3 million primarily due to current and prior year acquisitions.

Operating income increased \$16.8 million from \$38.5 million for the nine months ended September 29, 2017 to \$55.3 million for the nine months ended September 28, 2018. This increase was primarily attributable to an increase in gross profit of \$38.7 million as a result of higher revenue, partially offset by an increase in operating expenses of \$21.9 million primarily due to current and prior year acquisitions.

Diluted earnings per share (“Diluted EPS”) of \$0.60 for the three months ended September 28, 2018 increased \$0.60 from the prior year period. This increase was attributable to \$7.0 million higher net income attributable to Novanta Inc. and a \$14.5 million decrease in the Laser Quantum nontaxable redeemable noncontrolling interest redemption value adjustment from the prior year period. Diluted EPS for the three months ended September 28, 2018 was positively impacted by a \$6.9 million reduction in the redeemable noncontrolling interest redemption value, while Diluted EPS for the three months ended September 29, 2017 was negatively impacted by a \$7.6 million increase in the redeemable noncontrolling interest redemption value. (See Note 5 to the accompanying Consolidated Financial Statements.)

Diluted EPS of \$1.11 for the nine months ended September 28, 2018 decreased \$0.02 from the prior year period. This decrease was primarily attributable to the \$26.4 million nontaxable gain recognized from the acquisition of the additional approximately 35% of Laser Quantum equity interest in the prior year, partially offset by higher operating income overall and a \$13.1 million decrease in the Laser Quantum nontaxable redeemable noncontrolling interest redemption value adjustment from the prior year period. Diluted EPS for the nine months ended September 28, 2018 was positively impacted by a \$1.8 million redeemable noncontrolling interest redemption value adjustment, while Diluted EPS for the nine months ended September 29, 2017 was negatively impacted by an \$11.3 million redeemable noncontrolling interest redemption value adjustment. (See Note 5 to the accompanying Consolidated Financial Statements.)

Revenue

The following table sets forth external revenue by reportable segment for the periods noted (dollars in thousands):

	Three Months Ended		Increase (Decrease)	Percentage	
	September 28, 2018	September 29, 2017		Change	
Photonics	\$61,285	\$ 61,882	\$ (597)	(1.0)	%
Vision	62,113	58,150	3,963	6.8	%
Precision Motion	37,396	26,264	11,132	42.4	%
Total	\$160,794	\$ 146,296	\$ 14,498	9.9	%

	Nine Months Ended		Increase (Decrease)	Percentage	
	September 28, 2018	September 29, 2017		Change	
Photonics	\$187,178	\$ 170,503	\$ 16,675	9.8	%
Vision	172,145	124,943	47,202	37.8	%
Precision Motion	98,836	78,926	19,910	25.2	%
Total	\$458,159	\$ 374,372	\$ 83,787	22.4	%

Photonics

Photonics segment revenue for the three months ended September 28, 2018 decreased by \$0.6 million, or 1.0%, versus the prior year period primarily due to a decrease in revenue of our optical light engine products, partially offset by an increase in revenue of our laser beam delivery products and our CO2 laser products as a result of increased volumes in the advanced industrial market.

Photonics segment revenue for the nine months ended September 28, 2018 increased by \$16.7 million, or 9.8%, versus the prior year period primarily due to an increase in revenue across all of our product lines. Revenue from our laser beam delivery products increased \$11.3 million as a result of increased volumes in the advanced industrial market.

Vision

Vision segment revenue for the three months ended September 28, 2018 increased by \$4.0 million, or 6.8%, versus the prior year period primarily due to an increase in revenue of our minimally invasive surgery (“MIS”) products of \$3.1 million and our detection and analysis products of \$1.0 million as a result of increased demand in the medical market.

Vision segment revenue for the nine months ended September 28, 2018 increased by \$47.2 million, or 37.8%, versus the prior year period primarily as a result of the WOM acquisition in July 2017, which increased segment revenue by \$45.7 million.

Precision Motion

Precision Motion segment revenue for the three months ended September 28, 2018 increased by \$11.1 million, or 42.4%, versus the prior year period primarily due to an increase in revenue across all of our product lines as a result of increased demand in the advanced industrial market and the Zettlex acquisition in May 2018.

Precision Motion segment revenue for the nine months ended September 28, 2018 increased by \$19.9 million, or 25.2%, versus the prior year period primarily due to an increase in revenue across all of our product lines as a result of increased demand in the advanced industrial market and the Zettlex acquisition in May 2018.

Gross Profit and Gross Profit Margin

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Gross profit:				
Photonics	\$ 29,218	\$ 28,966	\$ 89,510	\$ 77,423
Vision	24,160	19,792	64,322	47,378
Precision Motion	16,788	10,291	44,750	34,558
Unallocated Corporate and Shared Services	(532)	(342)	(1,560)	(1,069)
Total	\$ 69,634	\$ 58,707	\$ 197,022	\$ 158,290
Gross profit margin:				
Photonics	47.7 %	46.8 %	47.8 %	45.4 %
Vision	38.9 %	34.0 %	37.4 %	37.9 %
Precision Motion	44.9 %	39.2 %	45.3 %	43.8 %
Total	43.3 %	40.1 %	43.0 %	42.3 %

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, headcount, inventory obsolescence and warranty expenses.

Photonics

Photonics segment gross profit for the three months ended September 28, 2018 increased \$0.3 million, or 0.9%, versus the prior year period. Photonics segment gross profit margin was 47.7% for the three months ended September 28, 2018, versus a gross profit margin of 46.8% for the prior year period. The increase in gross profit margin was primarily attributable to productivity improvements and reductions in cost of poor quality.

Photonics segment gross profit for the nine months ended September 28, 2018 increased \$12.1 million, or 15.6%, versus the prior year period, primarily due to an increase in revenue. Photonics segment gross profit margin was 47.8% for the nine months ended September 28, 2018, versus a gross profit margin of 45.4% for the prior year period. The increase in gross profit margin was primarily attributable to changes in product mix, productivity improvements and reductions in cost of poor quality. Amortization of inventory fair value adjustments and amortization of developed technologies also decreased \$1.6 million, which resulted in a 0.9 percentage point increase in gross profit margin.

Vision

Vision segment gross profit for the three months ended September 28, 2018 increased \$4.4 million, or 22.1%, versus the prior year period, primarily due to an increase in revenue. Vision segment gross profit margin was 38.9% for the three months ended September 28, 2018, versus a gross profit margin of 34.0% for the prior year period. The increase

in gross profit margin was primarily attributable to a decrease in amortization of inventory fair value adjustments and amortization of developed technologies of \$3.7 million, which resulted in a 6.0 percentage point increase in gross profit margin, partially offset by lower margins from our medical consumables products.

Vision segment gross profit for the nine months ended September 28, 2018 increased \$16.9 million, or 35.8%, versus the prior year period, primarily due to gross profit from the WOM acquisition. Vision segment gross profit margin was 37.4% for the nine months ended September 28, 2018, versus a gross profit margin of 37.9% for the prior year period. The decrease in gross profit margin was primarily attributable to unfavorable product mix, partially offset by a decrease in amortization of inventory fair value adjustments and amortization of developed technologies of \$2.0 million, which resulted in a 1.1 percentage point increase in gross profit margin.

Precision Motion

Precision Motion segment gross profit for the three months ended September 28, 2018 increased \$6.5 million, or 63.1%, versus the prior year period, primarily due to an increase in revenue. Precision Motion segment gross profit margin was 44.9% for the three months ended September 28, 2018, versus a gross profit margin of 39.2% for the prior year period. The increase in gross profit margin was primarily related to changes in product mix and reduction of cost of poor quality related to our supply chain.

Precision Motion segment gross profit for the nine months ended September 28, 2018 increased \$10.2 million, or 29.5%, versus the prior year period, primarily due to an increase in revenue. Precision Motion segment gross profit margin was 45.3% for the nine months ended September 28, 2018, versus a gross profit margin of 43.8% for the prior year period. The increase in gross profit margin was primarily related to changes in product mix and reduction of cost of poor quality related to our supply chain.

Operating Expenses

The following table sets forth operating expenses for the periods noted (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Research and development and engineering	\$ 13,204	\$ 11,659	\$ 37,744	\$ 29,878
Selling, general and administrative	29,147	27,590	87,598	74,274
Amortization of purchased intangible assets	3,947	3,217	11,538	9,413
Restructuring, acquisition and divestiture related costs	2,341	3,834	4,805	6,232
Total	\$ 48,639	\$ 46,300	\$ 141,685	\$ 119,797

Research and Development and Engineering Expenses

Research and development and engineering (“R&D”) expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were \$13.2 million, or 8.2% of revenue, during the three months ended September 28, 2018, versus \$11.7 million, or 8.0% of revenue, during the prior year period. R&D expenses increased in terms of total dollars and as a percentage of revenue primarily due to higher investments across the majority of our product lines and current year acquisitions.

R&D expenses were \$37.7 million, or 8.2% of revenue, during the nine months ended September 28, 2018, versus \$29.9 million, or 8.0% of revenue, during the prior year period. R&D expenses increased in terms of total dollars and as a percentage of revenue primarily due to higher investments across the majority of our product lines and current and prior year acquisitions.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were \$29.1 million, or 18.1% of revenue, during the three months ended September 28, 2018, versus \$27.6 million, or 18.9% of revenue, during the prior year period. SG&A expenses decreased as a percentage of revenue due to leverage. SG&A expenses increased in terms of total dollars primarily due to an increase in compensation as a result of higher headcount and stock-based compensation expense.

SG&A expenses were \$87.6 million, or 19.1% of revenue, during the nine months ended September 28, 2018, versus \$74.3 million, or 19.8% of revenue, during the prior year period. SG&A expenses decreased as a percentage of revenue due to leverage. SG&A expenses increased in terms of total dollars primarily due to an increase in costs from current and prior year acquisitions, and an increase in compensation as a result of higher headcount and stock-based compensation expense.

Amortization of Purchased Intangible Assets

Amortization of purchased intangible assets, excluding the amortization of developed technologies included in cost of revenue, was \$3.9 million, or 2.5% of revenue, during the three months ended September 28, 2018, versus \$3.2 million, or 2.2% of revenue, during the prior year period. The increase, in terms of total dollars and as a percentage of revenue, was the result of acquired intangible assets from current and prior year acquisitions.

Amortization of purchased intangible assets, excluding the amortization of developed technologies included in cost of revenue, was \$11.5 million, or 2.5% of revenue, during the nine months ended September 28, 2018, versus \$9.4 million, or 2.5% of revenue, during the prior year period. The increase, in terms of total dollars, was related to the increase in amortization of acquired intangible assets from current and prior year acquisitions.

Restructuring, Acquisition and Divestiture Related Costs

We recorded restructuring, acquisition and divestiture related costs of \$2.3 million during the three months ended September 28, 2018, versus \$3.8 million during the prior year period. Restructuring, acquisition and divestiture related costs in the three months ended September 28, 2018 included restructuring charges of \$0.1 million related to the 2018 restructuring program and acquisition related costs of \$2.2 million primarily associated with the Zettlex acquisition. We expect to incur additional restructuring charges of \$1.2 million to \$1.5 million related to the 2018 restructuring program through the third quarter of 2019. Restructuring, acquisition and divestiture related costs in the three months ended September 29, 2017 primarily included acquisition related costs related to an investment banking success fee related to the acquisition of WOM.

We recorded restructuring, acquisition and divestiture related costs of \$4.8 million during the nine months ended September 28, 2018, versus \$6.2 million during the prior year period. Restructuring, acquisition and divestiture related costs in the nine months ended September 28, 2018 included restructuring charges of \$1.1 million related to the 2018 restructuring program and acquisition related costs of \$3.7 million primarily associated with the Zettlex acquisition. Restructuring, acquisition and divestiture related costs in the nine months ended September 29, 2017 primarily included acquisition related costs related to professional services fees for acquisitions.

Operating Income (Loss) by Segment

The following table sets forth operating income (loss) by segment for the periods noted (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Operating Income (Loss)				
Photonics	\$ 14,595	\$ 15,367	\$46,102	\$ 36,138
Vision	5,380	846	6,246	4,893
Precision Motion	8,818	5,493	25,037	20,238
Unallocated Corporate and Shared Services	(7,798)	(9,299)	(22,048)	(22,776)
Total	\$ 20,995	\$ 12,407	\$55,337	\$ 38,493

Photonics

Photonics segment operating income was \$14.6 million, or 23.8% of revenue, during the three months ended September 28, 2018, versus \$15.4 million, or 24.8% of revenue, during the prior year period. The decrease in operating income was primarily due to an increase in R&D expenses of \$1.0 million.

Photonics segment operating income was \$46.1 million, or 24.6% of revenue, during the nine months ended September 28, 2018, versus \$36.1 million, or 21.2% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$12.1 million, partially offset by an increase in R&D expenses and SG&A expenses of \$2.8 million.

Vision

Vision segment operating income was \$5.4 million, or 8.7% of revenue, during the three months ended September 28, 2018, versus \$0.8 million, or 1.5% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$4.4 million.

Vision segment operating income was \$6.2 million, or 3.6% of revenue, during the nine months ended September 28, 2018, versus \$4.9 million, or 3.9% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit, partially offset by an increase in operating expenses from WOM, which was acquired in July 2017.

Precision Motion

Precision Motion segment operating income was \$8.8 million, or 23.6% of revenue, during the three months ended September 28, 2018, versus \$5.5 million, or 20.9% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$6.5 million, partially offset by an increase in R&D and SG&A expenses of \$1.2 million and an increase in acquisition earn-out costs of \$1.7 million associated with the Zettlex acquisition.

Precision Motion segment operating income was \$25.0 million, or 25.3% of revenue, during the nine months ended September 28, 2018, versus \$20.2 million, or 25.6% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of \$10.2 million, partially offset by an increase in R&D and SG&A expenses of \$2.5 million and an increase in acquisition earn-out costs of \$2.4 million associated with the Zettlex acquisition.

Unallocated Corporate and Shared Services

Unallocated corporate and shared services costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments, including certain restructuring and most acquisition related costs. These costs for the three months ended September 28, 2018 decreased by \$1.5 million versus the prior year period primarily due to a decrease in acquisition related costs of \$2.5 million related to an investment banking success fee related to the acquisition of WOM, partially offset by an increase in compensation as a result of higher headcount and stock-based compensation expense.

Unallocated corporate and shared services costs for the nine months ended September 28, 2018 decreased by \$0.7 million versus the prior year period primarily due to a decrease in acquisition related costs of \$3.7 million related to an investment banking success fee for the acquisition of WOM, partially offset by an increase in compensation as a result of higher headcount and stock-based compensation expense.

Other Income and Expense Items

The following table sets forth other income and expense items for the periods noted (in thousands):

	Three Months Ended		Nine Months Ended	
	September 28, 2018	September 29, 2017	September 28, 2018	September 29, 2017
Interest income (expense), net	\$ (2,396)	\$ (2,111)	\$ (7,315)	\$ (4,874)
Foreign exchange transaction gains (losses), net	66	(661)	(164)	(176)
Other income (expense), net	(44)	(138)	(131)	(288)
Gain on acquisition of business	—	—	—	26,409

Interest Income (Expense), Net

Net interest expense was \$2.4 million for the three months ended September 28, 2018, versus \$2.1 million in the prior year period. The increase in net interest expense was primarily due to an increase in the weighted average interest rate on our senior credit facilities. The weighted average interest rate on our senior credit facilities was 3.49% during the three months ended September 28, 2018, versus 3.10% during the three months ended September 29, 2017.

Net interest expense was \$7.3 million for the nine months ended September 28, 2018, versus \$4.9 million in the prior year period. The increase in net interest expense was primarily due to an increase in average debt levels as a result of current and prior year acquisitions and an increase in the weighted average interest rate on our senior credit facilities. The weighted average interest rate on our senior credit facilities was 3.55% during the nine months ended September 28, 2018 versus 3.41% for the nine months ended September 29, 2017.

Foreign Exchange Transaction Gains (Losses), Net

Foreign exchange transaction gains (losses), net, were less than \$0.1 million net gains for the three months ended September 28, 2018, versus \$0.7 million net losses in the prior year period primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro, and realized gains from foreign currency contracts.

Foreign exchange transaction gains (losses), net, were \$0.2 million net losses for both the nine months ended September 28, 2018 and the nine months ended September 29, 2017.

Other Income (Expense), Net

Net other expense was nominal for the three months ended September 28, 2018, versus \$0.1 million in the prior year period.

Net other expense was \$0.1 million for the nine months ended September 28, 2018, versus \$0.3 million in the prior year period. The decrease in net other expense was primarily due to a decrease in net periodic pension costs of our frozen U.K. defined benefit pension plan covering employees of a divested business.

Gain on Acquisition of Business

The gain on acquisition of business during the nine months ended September 29, 2017 was related to a nontaxable gain of \$26.4 million recognized upon gaining control of Laser Quantum in January 2017 as a result of acquiring an additional approximately 35% of its outstanding shares.

Income Taxes

Our effective tax rate for the three months ended September 28, 2018 was 19.5%, versus 11.9% for the prior year. Our effective tax rate of 19.5% for the three months ended September 28, 2018 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, including the benefit of the new 21% U.S. corporate income tax rate and estimated deductions for Foreign Derived Intangible Income under the U.S. Tax Cuts and Jobs Act (the "Tax Reform Act"), and U.K. patent box deductions and other tax credits; offset by non-deductible expenses recognized under an earn-out agreement in connection with the Zettlex acquisition.

Our effective tax rate for the nine months ended September 28, 2018 was 17.3%, versus 11.6% for the prior year. Our effective tax rate of 17.3% for the nine months ended September 28, 2018 differs from the Canadian statutory rate of 29.0% due to the mix of income earned in jurisdictions with varying tax rates, including the benefit of the new 21% U.S. corporate income tax rate and estimated deductions for Foreign Derived Intangible Income under the Tax Reform Act, U.K. patent box deductions and other tax credits, and windfall tax benefits upon vesting of certain equity awards during the period; offset by non-deductible expenses recognized under an earn-out agreement in connection with the Zettlex acquisition. During the nine months ended September 29, 2017, we reported a nontaxable gain of \$26.4 million on our previously-held Laser Quantum equity interest and wrote off \$1.5 million of Laser Quantum related deferred tax liability, which had a combined 13.7% favorable impact on the effective tax rate in the prior year.

Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest expense. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowing capacity under our revolving credit facility provides another potential source of liquidity for acquisitions. We may seek to raise additional capital, which could be in the form of bonds, convertible debt or equity, to fund business development activities or other future investing cash requirements, subject to approval by the lenders in the Second Amended and Restated Credit Agreement.

Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, a decrease in demand for our products, our ability to integrate current and future acquisitions, deterioration in certain financial ratios, availability of borrowings under our revolving credit facility, and market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the earnings and the distribution of funds from our subsidiaries. Local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to us. We cannot assure you that applicable laws and regulations and/or the terms of our indebtedness will permit our subsidiaries to provide us with sufficient dividends, distributions or loans when necessary.

As of September 28, 2018, \$81.0 million of our \$111.8 million cash and cash equivalents was held by subsidiaries outside of Canada and the United States. Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions by those local subsidiaries and to pay down borrowings under our revolving credit facility. Approximately 69.4% of our

outstanding borrowings under our Senior Credit Facilities (defined below) was held in our subsidiaries outside of Canada and the United States. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries. In certain instances, we have identified excess cash for which we may repatriate and have established liabilities for the expected tax cost. Because of our ownership structure, our foreign entities outside the U.S. are not considered controlled foreign corporations of the U.S. company, as defined under U.S. tax principles, and accordingly, the accumulated earnings of these foreign subsidiaries are not subject to the one-time toll charge under the Tax Reform Act.

Share Repurchase Plans

In October 2013, the Company's Board of Directors authorized a share repurchase plan (the "2013 Repurchase Plan") under which the Company may repurchase outstanding shares of the Company's common stock up to an aggregate amount of \$10.0 million. As of December 31, 2017, the Company had repurchased a cumulative total of 296 thousand shares under the 2013 Repurchase Plan for an aggregate purchase price of \$4.2 million at an average price of \$14.05 per share. During the nine months ended September 28, 2018, the Company repurchased 57 thousand shares for an aggregate purchase price of \$3.8 million at an average price of \$66.16 per share under the 2013 Repurchase Plan.

In October 2018, the Company's Board of Directors approved a new share repurchase plan (the "2018 Repurchase Plan") authorizing the repurchase of an additional \$25.0 million worth of common shares. The Company expects that share repurchases will be made under the 2018 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934 after the 2013 Repurchase Plan is completed.

Under both share repurchase plans, shares may be repurchased from time to time, at the Company's discretion, based on ongoing assessment of the capital needs of the business, the market price of the Company's common stock, and general market conditions. Shares may also be repurchased through an accelerated stock purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common stock to be purchased when the Company would otherwise be prohibited from doing so under insider trading laws. The share repurchase plans do not obligate the Company to acquire any particular amount of common stock. No time limit was set for the completion of the share repurchase programs, and the programs may be suspended or discontinued at any time. The Company expects to fund the share repurchases through cash on hand and future cash generated from operations.

Second Amended and Restated Credit Agreement

In May 2016, we entered into the second amended and restated senior secured credit agreement (the "Second Amended and Restated Credit Agreement"), consisting of a \$75.0 million, 5-year term loan facility and a \$225.0 million, 5-year revolving credit facility (collectively, the "Senior Credit Facilities"). The Senior Credit Facilities mature in May 2021. In August 2017, we entered into a third amendment (the "Third Amendment") to the Second Amended and Restated Credit Agreement. The Third Amendment increased the borrowing limit under the revolving credit facility commitment from \$225 million to \$325 million and reset the accordion feature to \$125 million for future expansion. Additionally, the Third Amendment increased the term loan balance from \$65.6 million to \$90.6 million.

On February 26, 2018, we entered into a fourth amendment (the "Fourth Amendment") to the Second Amended and Restated Credit Agreement. The Fourth Amendment increased the maximum consolidated leverage ratio from 3.00 to 3.50, increased the maximum consolidated leverage ratio for permitted acquisitions and stock repurchases from 2.50 to 3.00, increased the maximum consolidated leverage ratio for a designated acquisition from 3.00 to 3.50, and increased the maximum consolidated leverage ratio for four consecutive quarters following a designated acquisition from 3.50 to 4.00. The Fourth Amendment also made certain other technical changes to the Second Amended and Restated Credit Agreement.

Edgar Filing: NOVANTA INC - Form 10-Q

As of September 28, 2018, we had term loans of \$79.1 million and revolving loans of \$179.7 million outstanding under the Second Amended and Restated Credit Agreement.

The Second Amended and Restated Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum leverage ratio and a minimum fixed charge coverage ratio (as defined in the Second Amended and Restated Credit Agreement). The following table summarizes these financial covenants and our compliance therewith as of September 28, 2018:

	Requirement	Actual
Maximum consolidated leverage ratio	3.50	2.04
Minimum consolidated fixed charge coverage ratio	1.50	5.36

Cash Flows for the Nine Months Ended September 28, 2018 and September 29, 2017

The following table summarizes our cash flows, cash and cash equivalents, and unused and available funds under our revolving credit facility for the periods indicated (in thousands):

	Nine Months Ended	
	September 28, 2018	September 29, 2017
Net cash provided by operating activities	\$67,720	\$ 41,287
Net cash used in investing activities	\$(42,257)	\$(174,790)
Net cash provided by (used in) financing activities	\$(12,274)	\$ 155,098

	September 28, 2018	December 31, 2017
Cash and cash equivalents	\$ 111,814	\$ 100,057
Unused and available funds under revolving credit facility	\$ 145,252	\$ 175,547

Operating Cash Flows

Cash provided by operating activities was \$67.7 million for the nine months ended September 28, 2018, versus \$41.3 million for the prior year. Cash provided by operating activities for the nine months ended September 28, 2018 increased from the prior year primarily due to the increase in operating income.

Cash provided by operating activities for the nine months ended September 28, 2018 was positively impacted by an increase in our days payables outstanding, which increased from 43 days at December 31, 2017 to 48 days at September 28, 2018, and an increase in accrued expenses. The Company's growth in revenue of \$83.8 million and gross profit of \$38.7 million increased our outstanding trade receivables and inventories, which negatively impacted our cash provided by operating activities. During the nine months ended September 28, 2018, we paid \$2.8 million as the final Applimotion contingent consideration payment which had been accrued for as of December 31, 2017.

Cash provided by operating activities for the nine months ended September 29, 2017 was positively impacted by an increase in our outstanding payables and accrued expenses. Cash provided by operating activities was negatively impacted by an increase in outstanding trade receivables and an increase in inventories, excluding trade receivables and inventories acquired from acquisitions, and an increase in income tax payments.

Investing Cash Flows

Cash used in investing activities was \$42.3 million for the nine months ended September 28, 2018, primarily related to \$29.6 million cash outflows (net of cash acquired of \$3.8 million) related to the current year acquisitions, \$1.2 million in cash paid to acquire customer relationship assets, and \$11.6 million in capital expenditures.

Cash used in investing activities was \$174.8 million for the nine months ended September 29, 2017, primarily driven by our acquisitions of WOM, ThingMagic and Laser Quantum. In connection with these acquisitions, we paid \$185.0 million in cash considerations, which is reported in the consolidated statement of cash flows as \$168.3 million cash outflows from investing activities (net of cash acquired of \$16.7 million and working capital adjustments) for the nine months ended September 29, 2017. We also paid \$6.5 million for capital expenditures during the nine months ended September 29, 2017.

Financing Cash Flows

Cash used in financing activities was \$12.3 million for the nine months ended September 28, 2018, primarily due to \$30.7 million of cash consideration paid for the acquisition of the remaining equity interest in Laser Quantum, \$9.2 million of contractual term loan payments, \$19.9 million of optional repayments of borrowings under our revolving credit facility, \$3.5 million of payroll tax payments on stock-based compensation awards, \$3.8 million of repurchases of common stock and \$0.4 million of principal payments under our capital lease obligations, partially offset by \$55.3 million of borrowings under our revolving credit facility used to fund a portion of the cash consideration paid for the acquisition of Zettlex and the remaining equity interest in Laser Quantum.

Cash provided by financing activities was \$155.1 million for the nine months ended September 29, 2017, primarily due to \$176.8 million of borrowings under our revolving credit facility used to fund a portion of the cash considerations paid for the WOM, ThingMagic and Laser Quantum acquisitions, partially offset by \$5.6 million of contractual term loan payments, \$10.0 million of

optional repayments of borrowings under our revolving credit facility, \$2.5 million of contingent consideration payments, \$1.8 million of payroll tax payments on stock-based compensation awards, \$0.4 million of repurchase of common stock and \$0.6 million of principal payments under our capital lease obligations. We also paid \$0.6 million for debt issuance costs as a result of the Third Amendment to the Second Amended and Restated Credit Agreement entered into in August 2017.

Off-Balance Sheet Arrangements, Contractual Obligations

Contractual Obligations

Our contractual obligations primarily consist of the principal and interest associated with our debt, operating and capital leases, purchase commitments and pension obligations. Such contractual obligations are described in our Management's Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Excluding the £41.0 million borrowings under our revolving credit facility to fund the acquisition of Zettlex and the remaining 24% of outstanding shares of Laser Quantum, as well as the First Amendment to Amended and Restated Lease signed in May 2018 for our Bedford, Massachusetts headquarters, through September 28, 2018, we have not entered into any material new or modified contractual obligations since December 31, 2017. Borrowings under our revolving credit facility are due in May 2021, the maturity date of our Senior Credit Facilities, and may be repaid at any time before then without prepayment penalties. Our annual rental payment under the First Amendment to Amended and Restated Lease is \$1.8 million with 2.5% annual escalations. Total future minimum lease payments under the First Amendment to Amended and Restated Lease is \$26.4 million as of September 28, 2018.

Off-Balance Sheet Arrangements

Through September 28, 2018, we have not entered into any other off-balance sheet arrangements or material transactions with any unconsolidated entities or other persons.

Critical Accounting Policies and Estimates

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this periodic report on Form 10-Q are described in our Management's Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Except for the adoption of Accounting Standards Update ("ASU") 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09" or "Topic 606"), through September 28, 2018, there have been no material changes to our critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Recent Accounting Pronouncements

See Note 1 to Consolidated Financial Statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our primary market risk exposures are foreign currency exchange rate fluctuations and interest rate sensitivity. During the three months ended September 28, 2018, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of September 28, 2018, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 28, 2018.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter ended September 28, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of these claims will have a material adverse effect upon its financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon its financial condition or results of operations.

Item 1A. Risk Factors

The Company's risk factors are described in Part I, Item 1A, "Risk Factors", of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017. There have been no material changes in the risks affecting the Company since the filing of such Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table sets forth certain information with respect to repurchases of the Company's common shares during the three months ended September 28, 2018.

ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽¹⁾⁽²⁾	Approximate Dollar Value that May Yet Be Purchased Under the Plans or Programs ⁽¹⁾
July 2 - August 3, 2018	15,300	\$ 65.68	15,300	\$ 2,909,900
August 4 - August 31, 2018	4,000	\$ 71.14	4,000	\$ 2,625,321
September 1 - September 28, 2018	7,400	\$ 73.82	7,400	\$ 2,079,073
Total	26,700		26,700	

(1) In October 2013, the Company's Board of Directors authorized a share repurchase plan (the "2013 Repurchase Plan") for the repurchase of up to an aggregate of \$10.0 million of the Company's common shares. The share repurchase plan was announced in the quarterly report for the period ended September 27, 2013 filed on November 5, 2013. The shares may be repurchased from time to time, at the Company's discretion, based on ongoing assessment of the capital needs of the business, the market price of the Company's common shares, and general market conditions. No time limit was set for the completion of the share repurchase program, and the program may be suspended or discontinued at any time.

(2)The Company has repurchased 352,793 shares of its common shares pursuant to the 2013 Repurchase Plan since its adoption.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

43

Edgar Filing: NOVANTA INC - Form 10-Q

Item 6. Exhibits

List of Exhibits

See the Company's SEC filings on Edgar at: <http://www.sec.gov/> for all Exhibits.

Exhibit Number	Exhibit Description	Incorporated by Reference			Filing Date	Filed/ Furnished Herewith
		Form	File No.	Exhibit		
2.1	<u>Agreement on the Sale and Transfer of all Shares in W.O.M. World of Medicine GmbH, dated June 6, 2017, between Novanta Europe GmbH, Novanta Inc., and Aton GmbH.</u>	8-K	001-35083	2.1	06/09/17	
3.1	<u>Certificate and Articles of Continuance of the Registrant, dated March 22, 1999.</u>	S-3	333-202597	3.1	03/09/15	
3.2	<u>By-Laws of the Registrant, as amended</u>	10-Q	000-25705	3.2	04/13/10	
3.3	<u>Articles of Reorganization of the Registrant, dated July 23, 2010.</u>	8-K	000-25705	3.1	07/23/10	
3.4	<u>Articles of Amendment of the Registrant, dated December 29, 2010.</u>	S-3	333-202597	3.2	03/09/15	
3.5	<u>Articles of Amendment of the Registrant, dated May 11, 2016.</u>	8-K	001-35083	10.1	05/12/16	
10.1	<u>Novanta Inc. Non-Employee Director Compensation Policy.</u>					*
10.2	<u>Form of Director Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement.</u>					*
31.1	<u>Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>					*
31.2	<u>Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>					*
32.1	<u>Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>					**

32.2 Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **

101.INS XBRL Instance Document. *

101.SCH XBRL Schema Document *

101.CAL XBRL Calculation Linkbase Document. *

101.DEF XBRL Definition Linkbase Document. *

101.LAB XBRL Labels Linkbase Document. *

101.PRE XBRL Presentation Linkbase Document. *

* Filed herewith

** Furnished herewith

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets at September 28, 2018 and December 31, 2017, (ii) Consolidated Statements of Operations for the three and nine months ended September 28, 2018 and September 29, 2017, (iii) Consolidated Statements of Comprehensive Income

for the three and nine months ended September 28, 2018 and September 29, 2017, (iv) Consolidated Statements of Cash Flows for the nine months ended September 28, 2018 and September 29, 2017, and (v) Notes to Consolidated Financial Statements.

45

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Novanta Inc. (Registrant)

Name	Title	Date
/s/ Matthijs Glastra Matthijs Glastra	Director, Chief Executive Officer	November 6, 2018
/s/ Robert J. Buckley Robert J. Buckley	Chief Financial Officer	November 6, 2018